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Abstract	
The	vast	majority	of	studies	regarding	the	immunotherapeutic	potential	of	T	cells	have	focussed	
on	 CD8	 and	 CD4	 T	 cells	 that	 recognise	 tumor-associated	 peptide	 antigens	 (Ag)	 presented	 by	
polymorphic	 major	 histocompatibility	 complex	 (MHC)	 class	 I	 and	 MHC	 class	 II	 molecules,	
respectively.	However,	unconventional	T	cells,	which	 interact	with	MHC	class	 Ib	and	MHC-I	 like	
molecules,	 are	 also	 implicated	 in	 tumor	 immunity,	 although	 their	 role	 here	 is	 unclear.	 These	
include	 unconventional	 T	 cells	 targeting	MHC	 class	 Ib	molecules	 such	 as	 HLA-E	 and	 its	murine	
orthologue	 Qa-1b.	 Moreover,	 Natural	 Killer	 T	 (NKT)	 cells	 and	 Mucosal	 Associated	 Invariant	 T	
(MAIT)	cells	are	activated	by	 lipids	and	vitamin	B	metabolite	Ags	when	presented	by	the	MHC-
class	I-like	molecules	CD1	and	MR1,	respectively.	Additionally,	γδ 	T	cells	represent	a	distinct	T	cell	
lineage	that	interacts	with	a	range	of	ligands	spanning	MHC	molecules,	stress-induced	MHC	class	
I-like	 molecules,	 CD1	 molecules	 and	 butyrophylins.	 Considering	 that	 unconventional	 T	 cells	
frequently	 have	 repeated	 and	 predictable	 patterns	 of	 T	 cell	 receptor	 gene	 usage	 in	 unrelated	
individuals,	 and	 interact	with	monomorphic	 Ag-presenting	molecules,	 they	 have	 broad	 clinical	
potential	regardless	of	patient	MHC	genotype.	Here,	we	review	these	unconventional	T	cells	with	
a	focus	on	the	evidence	that	they	can	inhibit	tumor	growth	and	discuss	why	further	studies	into	
the	immunotherapeutic	potential	of	these	cells	is	warranted.		
	
Introduction	
T	 lymphocytes	 are	 a	 key	 component	 of	 the	 immune	 system	 and	 a	 major	 focus	 for	 cancer	
immunotherapy.	 The	 vast	 majority	 of	 studies	 into	 the	 immunotherapeutic	 potential	 of	 T	
lymphocytes	have	 focussed	on	conventional	CD8	T	cells	 that	 recognise	peptide	Ags	presented	by	
MHC	 class	 I	 molecules.	 Following	 activation,	 clonal	 expansion	 and	 differentiation,	 these	 cells	
become	 cytotoxic	 T	 lymphocytes	 (CTL)	 with	 the	 ability	 to	 target	 and	 kill	 tumor	 cells	 when	 they	
encounter	specific	tumor	peptide-MHC	class	I	complexes.	These	responses	can	also	be	enhanced	by	
engagement	 of	 CD4	 T	 cell	 help	 against	MHC	 class	 II	 restricted	 tumor	 peptide	 Ags	 (Coulie	 et	 al.,	
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2014;	 van	 der	 Burg	 et	 al.,	 2016).	 Approaches	 to	 harness	 anti-tumor	 CD8	 T	 cell	 responses	 using	
tumor	Ag-based	vaccines	have	yielded	some,	albeit	limited	success,	in	part	due	to	tumor	instability,	
peptide	stability(Purcell	et	al.,	2007)	and	the	tendency	of	tumors	to	modulate	expression	of	tumor	
Ags	and	MHC	molecules	(Coulie	et	al.,	2014;	van	der	Burg	et	al.,	2016).	Another	important	obstacle	
to	harnessing	CD4	and	CD8	T	cell	immunity	is	the	polymorphic	nature	of	the	MHC	(human	leucocyte	
antigen	(HLA))	proteins,	which	means	any	tumor	protein	or	peptide	Ag	must	contain	epitopes	that	
can	 be	 presented	 by	 the	 patient’s	 HLA	 type.	 Further,	 the	 polymorphic	 nature	 of	 the	MHC	 often	
infers	 a	 diverse	 responding	 T	 cell	 repertoire	 that	 is	 difficult	 to	 predict,	monitor	 and	 control.	 For	
example,	polymorphic	HLA	genotypes	also	limit	the	potential	for	the	use	of	‘off	the	shelf’	T	cell	or	
chimeric	Ag	receptor	(CAR)	T	cell	therapy	because	of	the	danger	of	graft-versus-host	disease.	Here,	
we	 will	 review	 the	 field	 of	 tumor	 immunity	 with	 a	 focus	 on	 the	 role,	 and	 under-explored	
therapeutic	 potential,	 of	 unconventional	 T	 cells	 that	 can	 target	 monomorphic	 Ag-presenting	
molecules	 and	 other	 ligands.	 This	 includes	 the	 MHC	 class	 Ib-restricted	 T	 cells,	 CD1	 and	 MR1	
restricted	 T	 cells,	 and	 γδ	 T	 cells	 (Figure	 1).	 Such	 unconventional	 T	 cells,	 which	 are	 often	
characterised	 by	 repeated	 patterns	 of	 TCR	 usage	 in	 unrelated	 individuals,	 have	 long	 been	
implicated	in	tumor	recognition	and	destruction.	
		
MHC	class	Ib-restricted	T	cells	
MHC	class	Ib	molecules	are	structurally	similar	to	classical	MHC	class	I	(MHC	class	Ia)	molecules,	but	
are	 essentially	monomorphic.	 Further,	 unlike	MHC	 class	 Ia,	MHC	 class	 Ib	molecules	 show	 tissue-
restricted	 expression,	 the	 capacity	 to	 assemble	 in	 the	 absence	 of	 peptide,	 or	 a	 propensity	 to	
present	“non-standard”	peptides	(Rodgers	and	Cook,	2005).	Collectively,	these	features	imbue	MHC	
class	 Ib	 molecules	 with	 the	 capacity	 to	 perform	 specialised	 functions	 that	 control	 immune	
responses,	potentially	including	anti-tumor	responses,	in	unique	ways.		
	
Owing	to	their	orthologous	nature	(Joly	and	Rouillon,	2006),	the	most	widely	studied	MHC	class	Ib	
molecules	are	HLA-E	in	humans	and	Qa-1b	in	mice.	Following	their	genetic	identification	over	thirty	
years	 ago	 (Koller	 et	 al.,	 1988;	 Stanton	 et	 al.,	 1978),	 both	 of	 these	molecules	were	 subsequently	
shown	to	acts	as	 ligands	for	members	of	the	NKG2-CD94	NK	receptor	family	(Braud	et	al.,	1998a;	
Vance	et	al.,	1998).	We	now	understand	that	the	function	of	HLA-E	and	Qa-1b	is	the	presentation	of	
peptides	 from	 leader	 sequences	 that	 are	 largely,	 but	 not	 exclusively,	 derived	 from	MHC	 class	 Ia	
molecules	(Braud	et	al.,	1997;	Braud	et	al.,	1998b).	Presentation	of	these	peptides	by	HLA-E	and	Qa-
1b	allows	the	 immune	system	a	secondary	means	to	monitor	cellular	health	and	homeostasis	via	
detection	of	ongoing	MHC	class	I	biosynthesis.	Under	normal	conditions,	the	presentation	of	these	
peptides	by	HLA-E	or	Qa-1b	results	in	ligation	of	NKG2A-CD94	receptors	and	the	transmission	of	an	
inhibitory	 signal	 via	 immunoreceptor	 tyrosine-based	 inhibitory	motifs	 (ITIM),	 preventing	 immune	
activation.	In	this	setting,	it	is	easy	to	envision	that,	by	promoting	the	expression	of	HLA-E,	tumors	
would	 be	 able	 to	 escape	 immune	 detection.	 However,	 HLA-E	 and	 Qa-1b	 are	 also	 ligands	 for	
activating	 NKG2C-CD94	 complexes,	 an	 interaction	 that	 leads	 to	 immune	 activation	 and	 target	
elimination.	 Thus,	 HLA-E	 and	 Qa-1b	 provide	 inhibitory	 and	 activating	 signals	 depending	 on	 the	
context	of	the	receptor	that	is	engaged.	This	understanding	provides	a	rationale	for	the	contrasting	
observations	that	HLA-E	expression	is	associated	with	poor	outcome	in	breast	and	cervical	cancer	
(de	 Kruijf	 et	 al.,	 2010;	 Gooden	 et	 al.,	 2011)	 yet	 can	 be	 used	 as	 a	 good	 prognostic	 indicator	 in	
glioblastoma	(Kren	et	al.,	2011),	colorectal	and	renal	cell	carcinoma	(Benevolo	et	al.,	2011;	Kren	et	
al.,	2012).	These	data	suggest	that,	by	itself,	HLA-E	may	not	be	a	useful	parameter	for	prognosis	but	
should	 be	 used	 in	 concert	 with	 the	 levels	 of	 infiltrating	 leukocytes	 expressing	 activating	 or	
inhibitory	forms	of	NKG2-CD94	(Versluis	et	al.,	2017).	
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Another	 human	 MHC	 class	 Ib	 molecule,	 HLA-G,	 is	 normally	 restricted	 in	 its	 expression	 to	
extravillous	 trophoblast	 cells	where	 it	 is	 thought	 to	 play	 an	 important	 role	 in	 immune	 tolerance	
during	pregnancy	(Ellis	et	al.,	1990;	Ferreira	et	al.,	2017;	Kovats	et	al.,	1990).	HLA-G	can	be	spliced	
into	multiple	isoforms	that	produces	4	membrane-bound	and	3	soluble	molecules	(Carosella	et	al.,	
2015).	The	major	soluble	(sHLA-G1	and	HLA-G5)	and	membrane	bound	HLA-G	(HLA-G1)	molecules	
are	 able	 to	 bind	 inhibitory	 receptors:	 Ig-like	 transcript-2	 (ILT2)	 and	 ILT4,	 which	 in	 turn	 transmit	
inhibitory	 signals	 via	 ITIMs	 (Shiroishi	 et	 al.,	 2003).	 In	 contrast	 to	 HLA-E,	 there	 is	 no	 opposing	
receptor	 that	 transmits	 an	 activating	 signal,	which	 could	make	 increased	HLA-G	an	opportunistic	
mechanism	 for	 tumor	 immune	 evasion.	 Indeed,	 the	 potential	 for	 HLA-G	 to	 regulate	 tumour	
immunity	is	highlighted	by	the	observation	that,	during	neoplastic	transformation	and	growth,	HLA-
G	becomes	prominent	in	hepatocellular	carcinoma	(Catamo	et	al.,	2014;	Lin	et	al.,	2010;	Park	et	al.,	
2012;	 Teixeira	 et	 al.,	 2013),	 colorectal	 and	 renal	 cancers	 (Rouas-Freiss	 et	 al.,	 2017;	 Swets	 et	 al.,	
2016),	 chronic	 myeloid	 leukaemia	 (CML)	 (Caocci	 et	 al.,	 2017)	 and	 glioma	 (Wang	 et	 al.,	 2015).	
However,	 the	 current	 data	 implicating	 HLA-G	 in	 tumour	 evasion	 is	 unclear.	 Meta-analysis	 of	 a	
mutation	 that	 increases	 HLA-G	mRNA	 stability,	 the	 14bp	 ins/del	 (Rousseau	 et	 al.,	 2003),	 has	 no	
prognostic	 value	 for	hepatocellular	 carcinoma(Coelho	et	 al.,	 2016).	 Furthermore,	while	 increased	
levels	of	 soluble	HLA-G	have	been	 identified	as	a	potential	prognostic	 indicator	during	 colorectal	
cancer	progression	(Kirana	et	al.,	2017;	Li	et	al.,	2017),	it	is	unclear	whether	increased	soluble	HLA-
G	 in	 this	 setting	 plays	 a	 role	 in	 suppressing	 the	 immune	 response.	 Modelling	 the	
immunosuppressive	effects	of	HLA-G	in	mouse	models	is	hampered	by	the	fact	that	no	homologue	
exists,	 hence,	 more	 sophisticated	 methods,	 including	 humanised	 mice	 (Nguyen-Lefebvre	 et	 al.,	
2016),	are	required.	
	
Animal	models	of	 cancer	and	MHC	class	 Ib	are	confounded	by	 the	 fact	 that	mice	have	 ten	 times	
more	MHC	 class	 Ib	 genes	 than	 humans.	 Furthermore,	 only	 HLA-E/Qa-1b	 demonstrate	 sufficient	
convergent	 evolution	 that	 their	 functionality	 is	 largely	 unchanged,	 yet	 this	 is	 complicated	by	 the	
observation	that	a	duplicate	of	Qa-1b	exists,	H2-T11,	which	has	almost	identical	functionality	(Chen	
et	al.,	2014).	Despite	 this,	 studies	have	 shown	 that	Qa-1b	plays	a	 critical	 role	 in	 the	detection	of	
cells	 that	 demonstrate	 Ag-processing	 defects.	 Using	 cells	 in	 which	 the	 TAP	 pathway	 has	 been	
disrupted,	Qa-1b	is	capable	of	presenting	a	wide	range	of	peptides	and	becomes	a	target	for	tumor	
control	and	CTL	activity	(Oliveira	et	al.,	2010).	This	suggests	that	Qa-1b	may	act	to	prevent	cancer	
by	limiting	neoplastic	transformation	of	cells	with	Ag-processing	defects.	While	HLA-E	can	present	
HLA-A-like	peptides	in	the	absence	of	TAP	(Lampen	et	al.,	2013),	the	role	of	HLA-E-restricted	T	cells	
in	tumors	is	yet	to	be	explored.	While	patients	with	TAP	deficiency	present	with	chronic	bacterial	
infections	of	the	airways,	they	are	capable	of	mounting	robust	CD8	T	cell	responses	and	there	is	no	
evidence	 to	 suggest	 increased	 cancer	 burden	 in	 these	 individuals	 (Zimmer	 et	 al.,	 2005).	
Interestingly,	 TAP-deficient	 patients	 demonstrate	 an	 increase	 in	 NKG2C+	 NK	 cells	 (Béziat	 et	 al.,	
2015),	 providing	 a	 potential	 clue	 as	 to	 the	 mechanism	 by	 which	 these	 patients	 control	 viral	
infections	and,	potentially,	cancer.	
	
With	respect	to	other	members	of	the	mouse	MHC	class	1b	family,	H2-M3	plays	an	important	role	
in	cancer	progression	through	the	education	of	specific	subsets	of	NK	cells	(Andrews	et	al.,	2012).	In	
the	absence	of	H2-M3,	Ly49A	expressing	NK	cells	do	not	reach	their	full	potential,	a	process	termed	
licensing,	 and	 are	 unable	 to	 contribute	 to	 the	 control	 of	 metastatic	 melanoma	 and	 chemically-
induced	fibrosarcoma	(Andrews	et	al.,	2012).		At	the	other	end	of	the	mouse	MHC	class	Ib	family,	
Qa-2	can	play	contrasting	roles	in	the	control	of	cancer.	In	one	setting,	Qa-2	acts	as	a	potent	CD8	
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restriction	element	and	allows	the	generation	of	 functionally	protective	memory	CTL	(Chiang	and	
Stroynowski,	 2004),	while	 also	 acting	 to	 prevent	NK	 cell	 control	 of	 tumors	 (Chiang	 et	 al.,	 2002).	
These	 two	 opposing	 effects	 provide	 a	 conundrum	 for	 immune	 editing	 of	 tumors	 whereby	
elimination	 of	 Qa-2	 expression	 will	 prevent	 recognition	 by	 CTL	 but	 also	 removes	 a	 potential	
inhibitory	 ligand	 for	 a	 receptor	 found	on	NK	 cells	 and	 activated/memory	CTL	 (Coles	 et	 al.,	 2000;	
Held	et	al.,	1995).	
	
Given	 the	 expression	 of	 human	MHC	 class	 Ib	molecules	 by	 tumors	 and	 their	 capacity	 to	 impair	
immune	 responses	 through	 specialised	 pathways,	 targeting	 these	 molecules	 as	 a	 cancer	
therapeutic	offers	potential.	However,	translating	observations	from	mouse	models	is	 limited	due	
to	species-based	differences	in	expression	and	function	of	these	molecules.	As	more	sophisticated	
models	of	human	MHC	class	 Ib	become	available,	our	understanding	of	 the	 role	 these	molecules	
play	in	modulating	anti-tumor	T	cells	will	increase,	which	could	ultimately	lead	to	their	assessment	
in	clinical	cancer	trials.	
	
CD1d	restricted	NKT	cells	
The	 CD1	 family	 of	 Ag-presenting	 molecules	 is	 divided	 into	 two	 groups:	 CD1a,	 CD1b,	 CD1c	 Ag-
presenting	molecules,	collectively	known	as	group	1	CD1	molecules,	and	CD1d	(group	2)	(Godfrey	
et	al.,	2015;	Van	Rhijn	et	al.,	2015).	 	CD1	molecules	are	MHC	class	 I-like,	but	 in	contrast	 to	MHC	
molecules,	these	possess	hydrophobic	Ag-binding	clefts	and	present	lipid-based	Ags	to	the	immune	
system	(Van	Rhijn	et	al.,	2015).	The	human	immune	system	harbors	populations	of	T	cells	with	the	
ability	to	recognise	diverse	lipid	Ags	presented	by	each	CD1	family	member	(Godfrey	et	al.,	2015;	
Van	Rhijn	et	al.,	2015).	While	many	of	the	lipid-based	Ags	described	thus	far	are	of	microbial	origin,	
a	growing	list	of	non-microbial	Ags,	including	tumor-derived	lipid	Ags,	are	presented	by	group	1	and	
group	 2	 CD1	 family	 members.	 The	 majority	 of	 studies	 have	 focussed	 on	 Ag	 recognition	 in	
association	with	CD1d,	partly	because	mice	express	 this	 family	member	but	not	 the	group	1	CD1	
molecules,	and	partly	because	 the	production	of	CD1d	tetramers	17	years	ago	has	 facilitated	the	
study	of	CD1d-restricted	T	cells	(Godfrey	et	al.,	2004).		
	
CD1d-restricted	T	cells	are	known	as	Natural	Killer	T	(NKT)	cells,	in	part	due	to	earlier	studies	that	
flagged	the	expression	of	NK	cell	molecules	such	as	NK1.1/CD161	by	these	T	cells	 (Godfrey	et	al.,	
2004).	 NKT	 cells	 can	 be	 divided	 into	 two	 broad	 types	 –	 based	 on	 their	 TCR	 usage	 and	 lipid	 Ag	
specificity.	 Type	 I	 NKT	 cells	 typically	 express	 semi-invariant	 TCRs	 comprised	 of	 TRAV11	 TRAJ18	
paired	with	a	limited	array	of	TCR-β	chains,	highly	enriched	for	TRBV13,	TRBV29	or	TRBV1	in	mice,	
or	 the	orthologous	TRAV10	TRAJ18	paired	with	TRBV25	 in	humans.	These	 type	 I	NKT	cells	are	all	
strongly	 reactive	 to	 the	glycosphingolipid	Ag	α-galactosylceramide	 (α-GalCer).	Conversely,	 type	 II	
NKT	cells	represent	a	broad	collection	of	T	cells,	excluding	α-GalCer-reactive	cells	with	the	invariant	
TCR-α	 chain,	 and	encompassing	 all	 other	CD1d-restricted	αβ T	 cells	 (Godfrey	et	 al.,	 2004).	 Some	
other	‘atypical’	NKT	TCRs,	including	αβ (Le	Nours	et	al.,	2016;	Uldrich	et	al.,	2011),	γδ	(Uldrich	et	al.,	
2013)	and	hybrid	δαβ	TCRs	(Pellicci	et	al.,	2014)	can	also	facilitate	recognition	of	α-GalCer	in	mice	
and	humans,	although	these	are	relatively	minor	subsets	of	α-GalCer-reactive	T	cells.	
	
Type	I	NKT	cells	are	abundant	in	mice,	representing	1%	or	more	of	T	cells,	while	in	humans	they	are	
much	less	frequent,	typically	ranging	between	0.01	and	0.1%	of	T	cells	(Godfrey	et	al.,	2015).	Many	
studies	 have	 demonstrated	 the	 potential	 for	 type	 I	 NKT	 cells	 to	 inhibit	 tumor	 growth	 in	 mice	
(recently	 reviewed	 in	 (McEwen-Smith	 et	 al.,	 2015;	 Nair	 and	 Dhodapkar,	 2017)).	 Indeed,	 the	 α-
GalCer	 Ag,	 originally	 derived	 from	 a	 marine	 sponge	 extract,	 first	 captured	 the	 attention	 of	
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immunologists	because	of	its	potent	anti-tumor	potential	in	mouse	tumor	models	(Kobayashi	et	al.,	
1995).	Only	subsequent	to	this	was	it	determined	that	α-GalCer	functioned	by	binding	to	CD1d	and	
stimulating	 type	 I	NKT	cells	 (Figure	2)	 (Kawano	et	al.,	 1997).	When	presented	by	CD1d,	α-GalCer	
activates	 type	 I	NKT	cells	which	 rapidly	produce	high	 levels	of	a	 range	of	 cytokines	 such	as	 IFNγ,	
TNF,	IL-4,	IL-13;	IL-17;	IL-21;	IL-22	(Coquet	et	al.,	2008;	Salio	et	al.,	2014).	Activated	NKT	cells	also	
express	cytotoxic	factors	such	as	perforin,	granzymes,	FAS-ligand	and	TRAIL	(McEwen-Smith	et	al.,	
2015;	Nair	and	Dhodapkar,	2017),	and	are	capable	of	directly	lysing	tumors	(Metelitsa	et	al.,	2001;	
Nicol	 et	 al.,	 2000;	 Smyth	 et	 al.,	 2002)	 although	 this	 is	 not	 the	 only	 means	 by	 which	 NKT	 cells	
mediate	anti-tumor	activity	(Hayakawa	et	al.,	2001;	Metelitsa,	2011;	Smyth	et	al.,	2002).	Activated	
NKT	cells	in	turn	activate	many	other	cells	of	the	immune	system,	and	in	particular,	dendritic	cells	
(DC)	 where	 a	multifactorial	 cross	 talk	 involving	 CD40L-CD40,	 IFNγ	 and	 IL-12	 production	 leads	 to	
increased	expression	of	CD80,	CD86,	CD70	and	IL-12	production	by	the	DC.	This	translates	to	more	
potent	 activation	 of	 conventional	 CD4	 and	 CD8	 T	 cells	 (Fujii	 et	 al.,	 2003;	 Hermans	 et	 al.,	 2003;	
Shimizu	et	al.,	2007;	Silk	et	al.,	2004;	Taraban	et	al.,	2008).	Type	I	NKT	cells	may	also	promote	an	
altered	 DC	 chemokine	 profile	 with	 CCL17	 and	 CCL22	 production	 driving	 the	 recruitment	 of	
functionally	distinct	CCR4+	CD8	T	cells	(Semmling	et	al.,	2010).	In	addition,	other	bystander	cells	are	
activated	 in	this	environment	that	contribute	to	tumor	rejection,	 including	NK	cells	 (Hayakawa	et	
al.,	 2001;	 Smyth	 et	 al.,	 2002),	 and	 γδ	 T	 cells	 (Paget	 et	 al.,	 2012),	 leading	 to	 enhanced	 effector	
function	at	many	levels.	Consequently,	targeting	type	I	NKT	cells	appears	to	engage	several	arms	of	
the	 immune	 system	 at	 once,	 reducing	 the	 potential	 for	 tumor	 escape	 from	 a	 more	 focussed	
immune	response.	Type	I	NKT	cells	can	also	target	tumor-associated	macrophages	(TAMs)	(Song	et	
al.,	 2009),	 myeloid-derived	 suppressor	 cells	 (MDSC)	 (De	 Santo	 et	 al.,	 2008),	 IL-10-secreting	
neutrophils	 (De	 Santo	et	 al.,	 2010)	 and	 ‘Nurse-like	 cells’	 associated	with	CLL	 (Gorini	 et	 al.,	 2017)	
thereby	indirectly	attacking	tumors	by	eliminating	immunosuppressive	stromal	support.		
	
The	adjuvant-like	activity	of	α-GalCer	can	be	harnessed	by	loading	it	directly	onto	DC	or	tumor	cells	
in	 vitro	 and	 transferring	 these	 cells	 injected	 back	 into	mice,	 which	 promotes	more	 potent	 anti-
tumor	 immunity	 by	 conventional	 CD8	 T	 cells	 compared	 to	 injecting	 this	 Ag	 as	 a	 free	 molecule	
(Shimizu	et	al.,	2007).	Tumors	can	also	be	directly	targeted	in	vivo	using	fusion	proteins	combining	
α-GalCer-CD1d	 to	 scFv	 fragments	 from	 tumor-specific	 antibodies	 (Stirnemann	 et	 al.,	 2008),	
focussing	 the	NKT	cell	 response	 to	 the	 tumor	 site,	 leading	 to	 strong	 inhibition	of	pre-established	
tumors	 compared	 to	 injection	 of	α-GalCer	 alone	 (Stirnemann	 et	 al.,	 2008).	 Another	 approach	 to	
combine	the	adjuvant	activity	of	α-GalCer	to	adaptive	CD8	T	cell	immunity	is	to	directly	conjugate	
α-GalCer	to	tumor	peptide	Ag,	focussing	both	NKT	cells	and	Ag-specific	CD8	T	cells	on	the	same	Ag-
presenting	cells,	 again	 leading	 to	enhanced	CD8	T	 cell-mediated	 tumor	 rejection	compared	 to	α-
GalCer	 alone	or	α-GalCer	mixed	with,	 but	 not	 conjugated	 to,	 peptide	Ag	 (Anderson	 et	 al.,	 2015;	
Speir	et	al.,	2017).	
	
Type	I	NKT	cells	can	contribute	to	tumor	surveillance	even	in	the	absence	of	exogenous	Ag	such	as	
α-GalCer.	CD1d	deficient	and/or	Jα18	(TRAJ18)	deficient	mice	that	lack	type	I	NKT	cells	can	be	more	
susceptible	to	tumor	development	and	growth	 including:	carcinogen-induced	sarcoma	(Nishikawa	
et	 al.,	 2005;	 Smyth	 et	 al.,	 2000;	 Swann	 et	 al.,	 2009);	 TRAMP-induced	 carcinoma	 (Bellone	 et	 al.,	
2010);	 transferred	 GM-CSF-secreting	 melanoma	 (Gillessen	 et	 al.,	 2003)	 and	 transferred	 B	
lymphoma	(Renukaradhya	et	al.,	2008).	These	findings	suggest	a	natural	protective	role	for	type	I	
NKT	 cells	 against	 a	 range	 of	 cancer	 types	 in	 mice.	 However,	 some	 caveats	 have	 subsequently	
emerged	 with	 the	 use	 of	 CD1d	 and	 Jα18-deficient	 mice:	 one	 study	 did	 not	 detect	 differential	
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susceptibility	 to	 carcinogen-induced	 sarcoma	 development	 in	 these	 mice	 (Kammertoens	 et	 al.,	
2011),	which	 they	suggested	may	be	due	 to	either	environment	or	genetic	drift	between	strains;	
CD1d-deficient	mice	unexpectedly	harbour	increased	numbers	of	MAIT	cells	compared	to	wildtype	
mice	 (Koay	et	 al.,	 2016),	which	may	have	 their	own	 immunomodulatory	effects	 and;	 the	original	
line	of	Jα18-deficient	mice	has	a	defect	in	the	use	of	other	Jα	genes	upstream	of	Jα18	(Bedel	et	al.,	
2012),	which	will	 impact	on	general	TCR	diversity.	Future	tumor	 immunosurveillance	studies	with	
CD1d-deficient	where	MR1	is	blocked	using	anti-MR1	antibody	(Huang	et	al.,	2005),	or	the	use	of	
CD1d-MR1	double-deficient	mice,	will	test	for	a	possible	influence	of	expanded	MAIT	cells	in	these	
studies.	New	lines	of	Jα18-deficient	mice	that	do	not	have	off-target	defects	in	the	use	of	upstream	
Jα	genes	(Chandra	et	al.,	2015;	Dashtsoodol	et	al.,	2016;	Zhang	et	al.,	2016)	will	also	be	valuable	for	
future	studies.	Nonetheless,	there	is	also	evidence	that	type	I	NKT	cells	play	a	naturally	protective	
role	 in	human	cancer.	Several	studies	have	shown	that	subnormal	type	I	NKT	cell	 frequencies	are	
associated	 with	 poor	 prognosis	 in	 cancer	 patients:	 for	 example,	 in	 head	 and	 neck	 carcinoma	
(Molling	et	al.,	2007);	acute	myeloid	leukemia	(Najera	Chuc	et	al.,	2012),	neuroblastoma	(Hishiki	et	
al.,	2018)	and	chronic	lymphocytic	leukemia	(Gorini	et	al.,	2017).	Indeed,	in	the	latter	study	(Gorini	
et	al.,	2017),	low	blood	NKT	cell	frequency	and	high	CD1d	expression	on	CLL	cells	were	significant	
predictors	 of	 CLL	 progression	 that,	 if	 combined	 with	 current	 prognostic	 factors	 such	 as	 CD38	
expression	 by	 CLL	 cells,	 may	 improve	 prognostic	 accuracy	 in	 this	 type	 of	 cancer.	 Conversely,	 a	
higher	 degree	of	NKT	 cell	 infiltration	 in	 colorectal	 cancer	 patients	was	 associated	with	 improved	
survival	(Tachibana	et	al.,	2005).		
	
Collectively,	these	reports	raise	the	important	question	of	what	tumor-associated	Ags	are	the	type	I	
NKT	cells	responding	to	in	these	settings?	For	many	years,	α-GalCer	was	viewed	only	as	a	foreign	
microbial	Ag	that	NKT	cells	were	unlikely	to	encounter.	However,	it	is	now	clear	that	this	glycolipid	
is	 produced	 by	 natural	 gut	 flora	 such	 as	 Bacteroides	 fragilis	 (Wieland	 Brown	 et	 al.,	 2013),	 and	
similar	molecules	such	as	α-psychosine	(Kain	et	al.,	2014)	and	α-Glucosylceramide	(Brennan	et	al.,	
2014)	are	produced	in	multiple	mammalian	tissues	and	can	also	be	detected	in	cow’s	milk	(Brennan	
et	al.,	2017).	Thus,	 it	 is	now	apparent	 that	α-linked	 type	 I	NKT	cell	 ligands	are	present	 in	normal	
healthy	 individuals.	 Furthermore,	 several	 studies	 have	 shown	 that	 tumor	 cells	modulate	 lipid	 Ag	
production	resulting	in	overrepresentation	of	some	lipids	that	may	be	antigenic	for	NKT	cells	when	
presented	in	the	context	of	CD1d,	such	as	isoglobotrihexosylceramide	(iGb3)	(Dias	et	al.,	2009),	the	
gangliosides	GD3	 and	GM3	 (Park	 et	 al.,	 2008;	Wu	et	 al.,	 2003),	 and	α-fucosylceramides	 that	 are	
associated	 with	 various	 types	 of	 human	 cancer	 including	 adenocarcinoma,	 colonic,	 gastric	 and	
pancreatic	carcinomas(Veerapen	et	al.,	2010)	(Figure	1).		
	
While	type	I	NKT	cells	are	known	for	their	ability	to	enhance	immunity	to	tumors	and	some	types	of	
infection,	they	also	have	great	 immunosuppressive	potential.	 Indeed,	some	of	the	earliest	studies	
of	 type	 I	 NKT	 cells	 were	 focussed	 on	 their	 ability	 to	 inhibit	 autoimmune	 diseases	 such	 as	
autoimmune	 (type	 1)	 diabetes	 and	 experimental	 autoimmune	 encephalomyelitis	 (EAE),	 and	 to	
prevent	graft	versus	host	disease	 (Godfrey	and	Kronenberg,	2004).	Accordingly,	 in	 two	studies	of	
haematological	malignancies	in	mice,	type	I	NKT	cells	appeared	to	inhibit	tumor	rejection	(Bjordahl	
et	 al.,	 2012;	 Renukaradhya	 et	 al.,	 2006).	 The	 paradoxical	 ability	 of	 type	 I	 NKT	 cells	 to	 either	
promote,	 or	 suppress,	 cell-mediated	 immunity	 may	 be	 partly	 associated	 with	 diverse	 cytokine	
production	 by	 functionally	 distinct	 subsets	 of	 these	 cells	 in	 response	 to	α-GalCer.	 These	 include	
IFNγ−producing	 ‘NKT1’	 cells,	 IL-4-producing	 ‘NKT2’	 cells,	 IL-10-producing	 ‘NKT10’	 cells	 and	 IL-17-
producing	‘NKT17’	cells	(Lee	et	al.,	2013;	Sag	et	al.,	2014),	although	a	recent	study	has	shown	that	
IL-4,	IL-10	and	IL-13	can	be	produced	at	similar	levels	by	NKT1,	NKT2	and	NKT17	cells	(Cameron	and	
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Godfrey,	 2018).	 	 These	 subsets	 have	 not	 been	 separately	 tested	 for	 their	 anti-tumor	 potential.	
However,	in	order	to	promote	stronger	tumor	rejection,	many	studies	have	explored	the	potential	
of	synthetic	analogues	of	α−GalCer	to	drive	a	type	I	NKT	cell	response	that	is	biased	toward	either	
pro-inflammatory/cell	mediated	outcomes,	or	anti-inflammatory	immunosuppressive	responses.		
	
Structurally,	α-GalCer	consists	of	a	α-D-galactose	headgroup	that	is	covalently	linked	to	both	fatty	
acid	and	phytosphingosine	chains	via	a	O-glycosidic	bond	(Figure	2).		The	first	crystal	structures	of	
hCD1d-α-GalCer	(Koch	et	al.,	2005),	mCD1d-α-GalCer	analogue	(Zajonc	et	al.,	2005),	type	I	NKT	TCR-
hCD1d-α-GalCer	and	 type	 I	NKT	TCR-mCD1d-α-GalCer	complexes	 (Borg	et	al.,	2007;	Pellicci	et	al.,	
2009)	(Figure	2)	provided	detailed	insights	into	the	molecular	basis	that	underpins	the	presentation	
by	CD1d	of	the	lipid-based	antigen	α-GalCer	and	its	subsequent	recognition	by	an	type	I	NKT	TCR.	In	
brief,	the	structural	studies	revealed	that	the	fatty	acid	and	phytosphingosine	chains	of	α-GalCer	sit	
deep	within	 the	 hydrophobic	 Aʹ-	 and	 Fʹ-pockets	 of	 CD1d,	 respectively,	while	 the	 polar	 galactose	
moiety	protrudes	out	of	 the	CD1d	binding	 cleft	 for	 recognition	by	 the	 type	 I	NKT	TCR	 (Figure	2),	
which	adopted	a	highly	 conserved	parallel	docking	mode	over	 the	Fʹ-pocket	of	 the	CD1d	binding	
groove	whereby	the	invariant	TCR	α-chain	made	key	interactions	with	the	2ʹ-,	3ʹ-	and	4ʹ-hydroxyls	
of	α-GalCer	and	CD1d,	while	the	NKT	TCR	β-chain	mediated	 interactions	exclusively	with	CD1d.	A	
number	 of	 CD1d	 residues	 also	 interacted	 closely	 with	 the	 O-glycosidic	 oxygen,	 the	 2ʹ-	 and	 3ʹ-
hydroxyls	of	α-GalCer,	and	 thus	 stabilizing	 the	Ag	within	 the	CD1d	cleft.	These	structural	 insights	
into	 the	CD1d-α-GalCer-type	 I	NKT	TCR	molecular	 interactions	provided	a	highly	valuable	rational	
basis	 to	 design	 novel	 classes	 of	 α-GalCer	 analogues	 (Figure	 2)	 that	 impact	 the	 type	 I	 NKT	 TCR	
recognition	and	direct	a	more	favourable	Th1	skewed	immune	response	for	cancer	therapy.	Indeed,	
presently	 the	molecular	 presentation	 and/or	 recognition	 of	 total	 of	 over	 20	 α-GalCer	 analogues	
have	been	investigated	structurally	although	fine	specificity	differences	between	mouse	and	human	
type	 I	 NKT	 cells	 may	 complicate	 translation	 of	 findings	 from	 mouse	 to	 human-based	 studies	
(Birkholz	 et	 al.,	 2015;	 Li	 et	 al.,	 2009;	 Wun	 et	 al.,	 2012).	 In	 brief,	 the	 introduced	 chemical	
modifications	 have	 been	 mainly	 targeting	 three	 distinct	 parts	 of	 the	 α-GalCer	 molecule	 that	
included	 the	 O-glycosidic	 bond,	 the	 glycolipid	 hydrophobic	 tails,	 and	 the	 galactose	 C6ʹ	 hydroxyl	
(Figure	2).	 Collectively,	 these	 approaches	have	 resulted	 in	new	glycolipid	 analogues	 such	as	α-C-
GalCer	(Patel	et	al.,	2011;	Schmieg	et	al.,	2003), aminocyclitolic	ceramide	(Kerzerho	et	al.,	2012),	β-
mannosylceramide	 (O'Konek	 et	 al.,	 2011),	 Nu-α-GalCer	 (Aspeslagh	 et	 al.,	 2011),	 PyrC-α-GalCer	
(Aspeslagh	et	al.,	2013),	α-GalCer	analogues	with	aromatic	 rings	 in	 their	acyl	or	 sphingosine	 tails	
(Chang	et	al.,	2007),	and	ABX196,	an	α-GalCer	analogue	with	an	acetamide	group	appended	to	the	
galactosyl	 C6	 (Tefit	 et	 al.,	 2014)	 (Figure	 2)	 that	 lead	 to	 improved	 pro-inflammatory	 cytokine	
polarization,	cell-mediated	immunity	and	anti-tumor	potential.		
	
A	number	of	clinical	trials	have	explored	α-GalCer-type	I	NKT	cell-based	immunotherapy	(Table	1).	
Early	trials	where	α-GalCer	was	injected	in	soluble	form	(Giaccone	et	al.,	2002)	or	pulsed	onto	DC	
(Chang	 et	 al.,	 2005;	 Ishikawa	 et	 al.,	 2005;	 Nieda	 et	 al.,	 2004),	 demonstrated	 that	 these	 agents,	
which	were	 generally	well-tolerated	with	 no	 serious	 complications,	 could	 induce	 type	 I	 NKT	 cell	
expansion,	 cytokine	 production	 and	 activation	 of	 bystander	 cells.	 One	 of	 these	 studies	 also	
reported	 that	 α-GalCer-pulsed	 mature	 DC	 led	 to	 long	 term	 enhanced	 production	 of	 CMV	 and	
influenza	virus	Ag	specific	memory	T	cells	(Chang	et	al.,	2005).	However,	these	interventions	had,	at	
best,	a	transient	stabilizing	effect	on	tumor	growth	in	a	subset	of	patients.	More	recent	trials	using	
α-GalCer	loaded	DC	injected	i.v.	or	into	tissues	(Kurosaki	et	al.,	2011;	Nagato	et	al.,	2012;	Nicol	et	
al.,	 2011a;	Richter	 et	 al.,	 2012;	Uchida	et	 al.,	 2008)	have	 further	demonstrated	 that	 this	 form	of	
	 8	
therapy	 has	 the	 potential	 to	 cause	 tumor	 regression	 or	 stabilise	 cancer	 growth	 in	 a	 subset	 of	
patients.	In	one	study,	α-GalCer	was	pulsed	onto	autologous	IL-2	and	GMCSF-cultured	PBMC,	which	
were	 then	 injected	 back	 into	 patients	 with	 advanced	 non-small	 cell	 lung	 cancer	 (NSCLC).	 In	 the	
majority	 (10	 out	 of	 17)	 of	 patients	 where	 a	 strong	 IFNγ	 response	 was	 observed,	 their	 median	
survival	time	was	31.9	months,	compared	to	~10	months	for	the	poor	responders,	which	is	closer	to	
expected	 for	 standard	 care	 for	 patients	 with	 advanced	 NSCLC	 (Motohashi	 et	 al.,	 2009).	 An	
additional	 approach	 has	 been	 to	 inject	 in	 vitro	 expanded	 and	 activated	 autologous	 NKT	 cells	
(Motohashi	et	al.,	2006)	 sometimes	 in	combination	with	α-GalCer	 loaded	dendritic	 cells	 (Kunii	et	
al.,	 2009;	 Yamasaki	 et	 al.,	 2011).	 A	 recent	 clinical	 trial	 has	 been	 reported	 where	α-GalCer	 was	
combined	 with	 a	 defined	 tumor	 protein	 Ag,	 NY-ESO-1,	 both	 loaded	 onto	 DC	 and	 injected	 into	
melanoma	patients	(Gasser	et	al.,	2017).	This	induced	a	sustained	increase	in	NY-ESO-1	responsive	
CD4	and	CD8	T	cells	 in	7	of	8	subjects,	highlighting	 the	potential	benefits	of	 targeting	 type	 I	NKT	
cells	in	association	with	tumor	Ag	vaccines.	While	these	reports	are	typically	from	small-scale	pilot	
studies	 or	 phase	 I	 or	 II	 trials,	 they	 are	 nonetheless	 providing	 encouraging	 results	 with	 tumor	
stabilisation	and	in	some	cases,	tumor	regression	(Table	1).	The	first	clinical	trial	with	an	enhanced	
potency	α-GalCer	analogue	(ABX196)	as	an	adjuvant	for	a	prophylactic	HepB	vaccine	was	recently	
reported	 (Tefit	 et	 al.,	 2014).	 This	work	 showed	 that	 type	 I	 NKT	 cell	 targeting	with	 this	 analogue	
could	 induce	 a	 potent	 anti-HepB	 antibody	 response	 from	 a	 single	 injection,	 comparable	 to	 the	
prime	 and	 boost	 response	 with	 the	 existing	 HepB	 vaccine	 with	 conventional	 Alum	 adjuvant.	 As	
HepB	 infection	 is	 associated	 with	 an	 increased	 risk	 of	 hepatocellular	 carcinoma,	 this	 highlights	
another	 potential	 means	 by	 which	 NKT	 cell	 targeting	 can	 be	 employed	 as	 a	 cancer	
immunotherapeutic.	Moreover,	the	successful	use	of	the	ABX196	analogue	in	this	setting	flags	the	
importance	 of	 testing	 this	 and	 other	α-GalCer	 analogues	 in	 direct	 anti-tumor	 clinical	 trials.	 The	
research	and	clinical	community	 is	awaiting	 larger	scale	clinical	 trials	 that	are	underway,	 to	more	
confidently	determine	the	potential	of	type	I	NKT	cell-based	immunotherapy.		
	
Another	interesting	development	in	the	use	of	type	I	NKT	cells	for	immunotherapy	is	the	generation	
of	chimeric	antigen	receptor	expressing	NKT	(CAR-NKT)	cells	(Heczey	et	al.,	2014;	Tian	et	al.,	2016).	
Human	type	I	NKT	cells	engineered	to	express	a	CAR	specific	for	the	GD2	ganglioside	that	is	highly	
expressed	 in	neuroblastoma	 (NB)	were	 cytotoxic	 against	human	NB	cells	 in	 vitro	 and	 in	 vivo	 in	 a	
humanised	NOD-SCID-IL2Rγnull	(NSG)	mouse	tumor	model.	Moreover,	while	both	GD2-specific	CAR-
T	 cells	 and	 CAR-NKT	 cells	were	 capable	 of	 infiltrating	 the	NB	 tumors,	 the	 CAR-NKT	 cells	 did	 this	
more	 effectively.	 Furthermore,	 CAR-T	 cells	 generated	 from	 an	 allogeneic	 donor	 caused	 severe	
GVHD	in	the	NSG	mice,	whereas	this	did	not	happen	with	GD2-specific	CAR-NKT	cells	(Heczey	et	al.,	
2014).	This	highlights	the	advantage	of	using	NKT	cells,	and	potentially	other	unconventional	T	cells,	
for	 ‘off	 the	 shelf’	 therapy	 because	 they	 are	 unlikely	 to	mount	 allogeneic	 responses	 against	 host	
MHC.	
	
Unlike	type	I	NKT	cells	that	have	repeated	patterns	of	TCR	usage,	the	type	II	NKT	cell	repertoire	is	
very	 diverse,	 and	 there	 is	 no	 universal	 type	 II	 NKT	 cell	 antigen	 that	 can	 be	 used	 to	 study	 this	
population	 of	 T	 cells.	 Consequently,	 the	 functional	 role	 of	 these	 type	 II	 NKT	 cells	 is	 less	 clear	
(recently	reviewed	in	(Dhodapkar	and	Kumar,	2017)),	although	important	to	establish	as	they	may	
be	 more	 prevalent	 in	 humans	 than	 type	 I	 NKT	 cells(Exley	 et	 al.,	 2001).	 While	 only	 a	 few	
investigations	into	the	role	of	type	II	NKT	cells	in	cancer	have	been	published,	most	studies	suggest	
these	 cells	 inhibit	 anti-tumor	 immunity.	 In	 a	 series	 of	 mouse-based	 studies	 comparing	 tumor	
growth	in	CD1d-deficient	(lacking	both	type	I	and	type	II	NKT	cells)	to	Jα18-deficient	(lacking	type	I	
but	retaining	type	II	NKT	cells),	notwithstanding	the	above-mentioned	caveats	with	these	mice,	the	
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data	 suggested	 that	 type	 II	 NKT	 cells	 suppress	 tumor	 rejection	 through	 the	 production	 of	 IL-13	
(Terabe	et	al.,	2005).	 In	 further	 support	 for	an	 immunosuppressive	 function	 for	 type	 II	NKT	cells,	
when	tumor	bearing	mice	are	treated	with	the	glycolipid	Ag	sulfatide,	which	is	presented	by	CD1d	
to	 a	 subset	 of	 type	 II	 NKT	 cells,	 tumor	 growth	 was	 exacerbated	 through	 production	 of	 IL-13	
(Ambrosino	 et	 al.,	 2007).	 Moreover,	 type	 II	 NKT	 cell-mediated	 suppression	 can	 antagonise	 the	
protective	 effects	 induced	 by	 α-GalCer-mediated	 type	 I	 NKT	 cell	 stimulation	 (Ambrosino	 et	 al.,	
2007;	Halder	et	al.,	2007).	A	more	recent	study	suggested	that	type	II	NKT	cells	and	Treg	cells	both	
play	 an	 immunosuppressive	 role	 and	 that	 blockade	 of	 both	 cell	 types	was	 necessary	 to	 prevent	
tumor	 immunosuppression	 when	 type	 I	 NKT	 cells	 are	 absent	 (Izhak	 et	 al.,	 2013).	 Another	
mechanism	 by	 which	 type	 II	 NKT	 cells	 may	 suppress	 tumor	 immunity	 is	 via	 induction	 of	 MDSC	
(Renukaradhya	et	al.,	2008),	which	notably	contrasts	with	the	inhibitory	effect	of	Type	I	NKT	cells	
on	MDSC	(De	Santo	et	al.,	2008).	In	a	study	of	multiple	myeloma	patients	(Chang	et	al.,	2008a),	the	
phospholipid	Ag	lysophosphatidylcholine	was	detected	at	increased	levels	of	blood	plasma,	as	well	
as	an	increased	population	of	type	II	NKT	cells	that	produced	IL-13	in	response	to	this	Ag,	compared	
to	 healthy	 individuals.	 It	 was	 suggested	 that	 this	 response	 might	 inhibit	 cell-mediated	 tumor	
immunity	and	promote	tumor	growth	in	these	patients	(Chang	et	al.,	2008a).	While	there	are	only	a	
few	studies	into	type	II	NKT	cells,	further	investigation	these	cells	and	the	role	they	play	in	human	
cancer	should	be	carried	out	as	they	may	represent	an	important	checkpoint	that	could	be	inhibited	
with	CD1d-blocking	antibodies.	
	
Group	1	CD1-restricted	T	cells.	
It	 is	 well	 known	 that	 CD1a,	 CD1b	 and	 CD1c	 restricted	 T	 cells	 are	 capable	 of	 presenting	
mycobacterial	lipid	Ags	to	human	T	cells	(Van	Rhijn	et	al.,	2015).	Furthermore,	recent	studies	have	
demonstrated	 that	 some	 T	 cells	 are	 capable	 of	 interacting	 with	 self-lipid	 Ags	 (Birkinshaw	 et	 al.,	
2015;	de	Jong	et	al.,	2010;	de	Lalla	et	al.,	2011;	Shahine	et	al.,	2017;	Van	Rhijn	et	al.,	2016;	Wun	et	
al.,	2018),	including	skin-derived	lipids	(de	Jong	et	al.,	2014)	presented	by	group	1	CD1	molecules.	
Moreover,	 some	 appear	 to	 interact	 solely	 with	 CD1a	 and	 CD1c	 in	 a	 response	 that	 is	 indirectly	
modulated	by	the	bound	lipid	Ag	(Birkinshaw	et	al.,	2015;	Wun	et	al.,	2018).	Furthermore,	CD1a,	b	
and	 c	 are	 expressed	 by	 human	 DC,	 so	 these	molecules	 are	 present	 in	 the	 tumor	 and/or	 tumor	
draining	 lymph	 node	 environment.	 This	 raises	 the	 question	 of	whether	Group	 I	 CD1	 restricted	 T	
cells	might	recognise	tumor-derived	lipid	Ags	and/or	whether	they	represent	new	targets	for	cancer	
immunotherapy.	In	one	study	(Lepore	et	al.,	2014),	CD1c	restricted	T	cells	were	found	to	recognise	
the	self-lipid	Ag	methyl-lysophosphatidic	acid	(mLPA)	(Figure	2)	that	 is	overrepresented	 in	human	
leukemia	 cells.	 These	 T	 cells	 were	 capable	 of	 killing	 human	 leukemia	 cells	 in	 vitro,	 and	 in	 a	
xenogeneic	mouse	 tumor	 transplantation	model.	 In	another	 study,	using	mice	 that	 transgenically	
expressed	 group	 1	 CD1	 molecules,	 CD1b-self-phospholipid-reactive	 T	 cells	 were	 capable	 of	
responding	to	tumor-derived	phospholipids	and	conferred	protection	against	a	CD1b-transfected	T	
cell	 lymphoma	 (Bagchi	 et	 al.,	 2016).	 Even	 if	 specific	 tumor	 lipid	Ags	 do	not	 exist	 for	 each	of	 the	
group	1	CD1	molecules,	 the	existence	of	known	 foreign	agonist	 ligands	 raises	 the	possibility	 that	
group	1	CD1-restricted	T	cells	 could	be	 targeted	 for	cancer	 immunotherapy,	much	 the	same	way	
that	 type	 I	 NKT	 cells	 can	 be	 targeted	 with	 the	α-GalCer.	 For	 example,	 most	 humans	 harbour	 a	
population	of	CD1b-restricted	T	cells	known	as	 ‘germline	encoded	mycolyl-reactive’	 (GEM)	T	cells	
that	 express	 an	 invariant	 TRAV1-2-TRAJ9	 TCR-α	 chain	 (Van	 Rhijn	 et	 al.,	 2013).	 This	 TCR	 imbues	
these	 cells	with	 specificity	 for	 the	mycobacterial	 lipid	Ag	 glucose	monomycolate,	 and	 these	 cells	
rapidly	produce	IFNγ	upon	Ag	encounter.	It	is	noteworthy	that	glucose	monomycolate	is	present	in	
the	mycobacterial	bacillus	Calmette	Guerin	 (BCG)	vaccine	 strain,	 and	 that	BCG-based	 therapy	 for	
non-muscular	bladder	cancer	has	been	successfully	for	many	years(Morales	et	al.,	1976).	Given	that	
	 10	
the	mechanism	 of	 action	 for	 BCG-based	 immunotherapy	 is	 unclear,	 but	 involves	 both	 CD4+	 and	
CD8+	T	cells	 (Redelman-Sidi	et	al.,	2014)	and	 that	 the	majority	of	BCG-responsive	CD8	T	cells	are	
CD1a,	 b	 or	 c	 restricted	 (Kawashima	 et	 al.,	 2003),	 the	 potential	 for	 mycobacterial	 lipid-based	
immunotherapy	to	target	group	1	restricted	T	cells	like	GEM	T	cells	is	worthy	of	further	exploration.	
	
While	 group	 1	 CD1	 restricted	 T	 cells	 are	 prevalent	 in	 humans,	 their	 role	 in	 immunity	 and	 tumor	
immunology,	is	not	well-understood,	principally	as	group	1	CD1	molecules	are	not	present	in	mice	
and	group	1	CD1	tetramers	to	identify	these	cells	have	only	become	available	in	the	last	few	years	
((Kasmar	et	al.,	2011;	Kasmar	et	al.,	2013;	Ly	et	al.,	2013),	see	http://tetramer.yerkes.emory.edu/).		
Considering	 the	 well-established	 role	 that	 the	 type	 I	 NKT	 cells	 play	 in	 tumor	 immunity,	 further	
investigations	in	humans,	and	in	group	1	CD1	transgenic	mice,	are	required	in	order	to	determine	
the	cancer	immunotherapeutic	potential	of	group	1	CD1-restricted	T	cells.		
	
Mucosal	associated	invariant	T	(MAIT)	cells		
MAIT	 cells	 are	 innate-like	 T	 cells	 found	 in	 mammals,	 whose	 frequency	 varies	 between	 species	
(Godfrey	 et	 al.,	 2015).	 	 For	 example,	whilst	 abundant	 in	 humans	 they	 are	much	 less	 frequent	 in	
laboratory	 strains	 of	mice	 (Rahimpour	 et	 al.,	 2015;	 Reantragoon	et	 al.,	 2013;	 Tilloy	 et	 al.,	 1999).	
MAIT	cells	reside,	as	their	name	implies,	in	the	mucosa,	and	are	also	found	in	the	peripheral	blood,	
and	organs	such	as	the	liver.	Although	the	physiological	and	pathophysiological	roles	for	MAIT	cells	
are	unclear,	 it	 is	 known	 that	many	bacteria	and	yeast	activate	MAIT	 cells	 via	 the	MAIT	TCR-MR1	
axis(Gold	et	al.,	2010;	Le	Bourhis	et	al.,	2010).	Moreover,	MAIT	cells	can	be	activated	by	viruses	in	a	
MAIT	 TCR-independent	 manner	 (Loh	 et	 al.,	 2016;	 van	Wilgenburg	 et	 al.,	 2016).	 	 MAIT	 cells	 are	
thought	to	play	a	role	 in	protective	 immunity	to	bacteria	(Chen	et	al.,	2016;	Howson	et	al.,	2018;	
Meierovics	et	al.,	2013),	and	are	reported	to	be	depleted	during	infection	by	viruses(Ussher	et	al.,	
2018),	which	 is	 considered	 to	 increase	host	 susceptibility	 to	opportunistic	 infections.	 In	 addition,	
MAIT	 cells	 are	 also	 implicated	 in	 several	 autoimmune	 disorders	 (Godfrey	 et	 al.,	 2015),	 including	
diabetes	(Magalhaes	et	al.,	2015;	Rouxel	et	al.,	2017).		
	
In	some	regards,	MAIT	cells	are	reminiscent	of	type	I	NKT	cells,	rapidly	secreting	cytokines	including	
IFN-γ,	TNF	and,	 in	some	situations	 IL-17,	 following	TCR-mediated	activation	 (Salio	et	al.,	2014).	 In	
line	with	 their	 innate-like	phenotype,	 the	majority	of	MAIT	 cells	 typically	possess	a	highly	biased	
TCR	 repertoire,	 characterised	 by	 a	 near-invariant	 TCR	 α-chain	 (TRAV1-2-TRAJ33	 or	 TRAJ12	 or	
TRAJ20)	 and	 a	 biased	 usage	 of	 TCR	 β	 chains	 (TRBV6	 or	 TRBV20),	 although	 the	 CDR3β loop	 is	
hypervariable(Eckle	et	al.,	2014;	Porcelli	et	al.,	1993;	Reantragoon	et	al.,	2013;	Tilloy	et	al.,	1999).	In	
contrast	to	type	I	NKT	TCR,	the	MAIT	TCR	recognises	the	MHC-I	related	molecule,	MR1(Treiner	et	
al.,	 2003).	 However,	 while	 MR1	 is	 expressed	 in	 all	 cell	 types,	 endogenous	 MR1	 cell	 surface	
expression	 is	 low,	and	 it	 is	 known	 that	 the	presence	of	MR1	 ligands	are	 required	 to	enable	MR1	
egress	to	the	cell	surface(McWilliam	et	al.,	2016).	These	MR1	ligands	were	identified	as	vitamin	B-
related	 ligands	 that	 bound	 MR1	 and	 activated	 MAIT	 cells	 with	 varying	 potencies	 (Figure	 3).	
Specifically,	while	MR1	bound	to	pterins	(metabolites	of	folic	acid	(vitamin	B9))	such	as	6-FP	and	the	
synthetic	 analogue	 acetyl-6-FP	 (Ac-6-FP),	 they	 typically	 do	 not	 activate	MAIT	 cells	 (Awad	 et	 al.,	
2018).	 In	 contrast,	 ribityllumazines	 (precursors	 to	 riboflavin	 (vitamin	 B2))	 bind	 MR1	 and	 also	
activate	MAIT	cells	weakly,	while	the	most	potent	agonists	were	derived	through	condensation	of	
an	 intermediate	 (5-amino-6-D-ribitylaminouracil,	 5-A-RU)	 in	 riboflavin	 biosynthesis	with	 glycolysis	
metabolites	 produced	 by	 bacteria	 and	 humans	 to	 form	 ribityluracils	 (e.g.	 5-(2-
oxopropylideneamino)-6-D-ribitylaminouracil,	 5-OP-RU)	 (Corbett	 et	 al.,	 2014;	 Kjer-Nielsen	 et	 al.,	
2012;	 Patel	 et	 al.,	 2013).	 Further,	 it	 has	 recently	 been	 demonstrated	 that	 MR1	 can	 present	 a	
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broader	 range	 of	 chemical	 scaffolds,	 including	 drugs	 and	 drug-like	molecules(Keller	 et	 al.,	 2017),	
which	 suggest	 that	 other	 endogenous	 ligands,	 can	 modulate	 MAIT	 cell	 function	 in	 an	 MR1-
dependent	manner.	Using	these	5-OP-RU	and	6-FP/Ac-6-FP	 ligands,	MR1-Ag	tetramers	have	been	
generated	that	permit	MAIT	cell	phenotyping	ex	vivo	in	an	Ag-specific	manner	(Corbett	et	al.,	2014;	
Rahimpour	et	al.,	 2015;	Reantragoon	et	al.,	 2013).	Using	 these	 tetramers	 (which	are	now	readily	
available	 from	 the	 NIH	 tetramer	 facility,	 http://tetramer.yerkes.emory.edu/),	 previously	
unrecognised	 subsets	 of	 MAIT	 cells	 are	 being	 identified,	 including	 immature	 precursors	 (Ben	
Youssef	et	al.,	2018;	Koay	et	al.,	2016)	and	MR1-restricted	TRAV1-2-	T	cells	 that	bind	 to	5-OP-RU	
and/or	 folate-derived	 ligands	6-FP	 and	Ac-6-FP	 (Gherardin	 et	 al.,	 2016).	 Further,	 the	use	of	MR1	
tetramers	 has	 enabled	 the	 division	 of	 human	 MAIT	 cells	 in	 peripheral	 blood	 into	 five	 subsets	
(CD4+CD8α-;	CD4+CD8α+;	CD4-CD8α-;	CD4-CD8α+CD8β-;	CD4-CD8α+CD8β+)	and	that	CD4+CD8α-	
MAIT	cells	are	phenotypically	and	functionally	distinct	from	other	MAIT	cell	subsets	(Gherardin	et	
al.,	2018b;	Kurioka	et	al.,	2017).	These	reports	should	provide	a	valuable	baseline	for	future	studies	
examining	MAIT	cells	in	human	cancers.	
	 	
While	 there	are	no	known	MR1-binding	tumor	Ags	 that	activate	MAIT	cells,	 it	 is	conceivable	 that	
MAIT	cells	may	encounter	microbial	Ags	in	tumor	types,	such	as	mucosal	cancers,	where	bacterial	
infiltrates	are	likely	to	be	present.	Furthermore,	as	observed	in	viral	infections	(Ussher	et	al.,	2018),	
MAIT	 cells	 can	 be	 activated	 in	 the	 presence	 of	 inflammatory	 cytokines,	 such	 as	 IL-12	 and	 IL-18,	
without	specific	Ag	stimulation.	TRAV1-2The	first	report	to	document	the	presence	of	MAIT	cells	in	
human	 cancers	 showed	 the	 presence	 of	 TRAV1-2-TRAJ33	 transcripts	 that	were	 enriched	 in	 brain	
and	 kidney	 tumors	 (Peterfalvi	 et	 al.,	 2008).	More	 recently,	 in	 a	 study	 of	 cancer	 patients	 with	 a	
variety	 of	 cancer	 types,	MAIT	 cells	 (defined	 by	 co-expression	 of	 surrogate	markers	 TRAV1-2	 and	
CD161	 or	 CD218)	 were	 found	 to	 be	 diminished	 in	 the	 circulation	 of	mucosal-associated	 cancers	
(gastric,	colon	and	lung),	but	not	in	association	with	non-mucosal	cancers	(breast,	liver	and	thyroid)	
(Won	et	al.,	2016).	Furthermore,	in	a	group	of	colon	cancer	patients,	where	circulating	MAIT	cells	
were	 diminished,	 increased	MAIT	 cell	 frequencies	 were	 detected	 amongst	 the	 tumor	 infiltrating	
cells	suggesting	that	they	were	recruited	from	blood	to	the	tumor	site	(Won	et	al.,	2016).	Similar	
findings	have	been	reported	in	other	studies	of	MAIT	cells	in	colorectal	cancer	patients	(Ling	et	al.,	
2016;	Sundstrom	et	al.,	2015;	Zabijak	et	al.,	2015),	where	increased	MAIT	cells	are	observed	in	the	
tumor	 infiltrate	compared	 to	adjacent	healthy	colon.	Moreover,	patients	with	a	higher	degree	of	
infiltrating	MAIT	cells	had	a	significantly	worse	prognosis	(Zabijak	et	al.,	2015).		
	
Because	MAIT	cells	are	highly	abundant	 in	human	 liver	 (Dusseaux	et	al.,	2011;	Tang	et	al.,	2013),	
the	role	that	these	might	play	in	liver-localised	cancers	is	of	particular	interest.	One	study	reported	
that	MAIT	 cells	 are	 present	 in	 both	 the	 healthy	 parts	 of	 liver	 as	 well	 as	 the	 tumor	 infiltrate	 in	
colorectal	 liver	metastasis	patients,	but	those	isolated	from	the	tumor	margin,	or	from	within	the	
tumor,	 were	 functionally	 impaired	 in	 their	 ability	 to	 produce	 IFN-γ	 (Shaler	 et	 al.,	 2017).	 Along	
similar	lines,	a	single	cell	sequencing	study	of	hepatocellular	carcinoma	patient	liver	samples,	MAIT	
cells	were	found	to	be	abundant	in	healthy	liver	tissue,	but	diminished	in	number	in	the	tumour	site	
(Zheng	 et	 al.,	 2017).	Moreover,	 reduced	MAIT	 cell	 frequencies	 appeared	 to	 correlate	 with	 poor	
prognosis	 in	these	patients	(Zheng	et	al.,	2017).	These	studies	suggest	that	inhibition	of	MAIT	cell	
infiltration	 and/or	 function	may	 be	 important	 for	 tumor	 survival.	 In	multiple	myeloma	 patients,	
MAIT	cells	are	also	numerically	and	functionally	diminished	in	blood	and	bone	marrow	(tumor	bed),	
although	 in	 part	 this	may	 reflect	 the	 older	 ages	 of	 these	 patients	 (Gherardin	 et	 al.,	 2018a).	 This	
study	also	showed	that	myeloma	cell	lines	expressed	cell	surface	MR1,	which	was	increased	in	the	
presence	 of	 the	MR1-binding	 antigen	 6-FP,	 and	MAIT	 cells	were	 capable	 of	 targeting	 and	 killing	
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myeloma	cell	lines	pulsed	with	the	agonist	ligand	5-OP-RU,	highlighting	the	anti-tumor	potential	of	
MAIT	cells	(Gherardin	et	al.,	2018a).	Interestingly,	the	immunomodulatory	drugs	lenalidomide	and	
pomalidomide,	 used	 to	 treat	 multiple	 myeloma	 patients,	 inhibited	MAIT	 cell	 activation	 in	 vitro,	
which	may	be	an	undesirable	effect	of	these	drugs.	Considering	that	 infection	is	a	major	problem	
for	multiple	myeloma	patients,	the	impact	of	diminished	MAIT	cell	numbers	and	function	should	be	
further	investigated.	
	
The	central	mechanistic	questions	in	the	MAIT-MR1-cancer	axes	are:	(1)	Can	MR1	present	tumor-
associated	antigens	to	MAIT	cells;	(2)	Is	MR1	is	overexpressed	in	certain	tumor	types	and	is	there	
stress-induced	expression	of	MR1	in	transformed	cells;	(3)	Do	MAIT	cells	play	a	pro-	or	anti-tumor	
role	 in	 the	 response	 to	 cancer;	 and	 (4)	 Do	 MAIT	 cells	 respond	 directly	 to	 tumors	 or	 do	 they	
modulate	the	activity	of	other	immune	cells.	Further	studies	could	compare	tumor	development	in	
MR1-deficient	 mice	 that	 lack	 MAIT	 cells	 to	 wildtype	 MAIT	 cell-sufficient	 mice.	 Mice	 that	 have	
increased	MAIT	 cells	 such	 as	 C57BL/6CAST	 congenic	mice	 (Cui	 et	 al.,	 2015b),	 or	where	MAIT	 cells	
have	been	 expanded	 in	 vivo	 (Chen	 et	 al.,	 2017)	may	provide	 a	 better	 indication	of	 the	 role	 that	
MAIT	cells	play	in	cancer,	whereas	Va19	TCR	transgenic	mice	might	not	be	helpful	for	these	studies	
as	 their	MAIT	 cells	 appear	 to	 be	 developmentally	 and	 functionally	 altered	 compared	 to	 those	 in	
non-transgenic	 mice	 (Koay	 et	 al.,	 2016).	 Complementing	 the	 use	 of	 different	 MAIT-deficient	 or	
sufficient	mouse	strains,	the	use	of	MAIT	cell	agonist	ligands	such	as	5-OP-RU	(Corbett	et	al.,	2014)	
to	 activate	MAIT	 cells	 in	 the	 context	 of	 tumor	 development	 in	 vivo	 is	 also	 a	 logical	 approach	 to	
investigating	 the	 anti-tumor	 potential	 of	 these	 cells.	 Addressing	 such	 questions	 will	 ultimately	
enable	one	to	consider	using	MAIT	cells,	or	CAR-MAIT	cells,	or	MAIT	cell	ligands,	in	novel	forms	of	
tumor	immunotherapy.	
	
γδ	T	cells		
γδ	T	cells	represent	~1-5%	of	circulating	human	T	cells,	and	in	humans	they	can	be	broadly	divided	
into	two	subsets	based	on	their	TCR	δ-chain	V	region	usage:	TRDV2+	cells,	which	co-express	TRGV9,	
and	TRDV2-	cells,	which	pair	with	an	array	of	TRGV	genes.	TRDV2+	cells	are	normally	more	abundant	
in	 the	 circulation	and	 react	 to	 small	 phosphorylated	metabolite	Ags,	 known	as	phosphoantigens,	
that	are	typically	derived	from	foreign	pathogens,	but	are	also	produced	by	mammalian	cells	and	
can	 lead	to	 increased	expression	by	 tumor	cells.	The	TRDV2-	cells	often	utilize	TRDV1+	or	TRDV3+	
TCRs	 and	 localize	 to	 peripheral	 sites	 such	 as	 skin	 and	 large	 intestine.	 There	 is	 only	 limited	
knowledge	about	 their	Ag	 reactivity,	 although	some	can	 react	with	MHC-I	 like	molecules	 such	as	
MICA,	CD1	and	EPCR,	or	soluble	Ags	in	the	absence	of	Ag-presentation,	in	sharp	contrast	to	other	
types	of	 T	 cells	 (reviewed	 in	 (Godfrey	et	 al.,	 2015;	Vantourout	and	Hayday,	2013)).	 Interestingly,	
some	TRDV1+	γδ	T	cells	can	respond	to	α-GalCer	presented	by	CD1d	in	humans(Uldrich	et	al.,	2013),	
which	 may	 be	 relevant	 in	 human	 trials	 involving	 this	 Ag.	 While	 γδ	 T	 cells	 in	 mice	 share	 some	
common	innate-like	functions	with	human	γδ	T	cells,	they	notably	differ	significantly	with	respect	
to	TCR	specificity	and	tissue	homing.	In	mice,	γδ	T	cell	subsets	are	normally	defined	by	TCRγ	chain	
usage,	and	typically	enriched	in	peripheral	sites	such	as	skin,	intestine,	liver,	lungs	and	reproductive	
tract	(Godfrey	et	al.,	2015).	
	
While	 the	major	 focus	 for	 the	 function	 of	 γδ	 T	 cells	 has	 been	 their	 role	 in	 homeostasis,	 wound	
repair	and	infection	(Nielsen	et	al.,	2017),	there	is	also	great	interest	in	the	role	that	these	cells	play	
in	cancer,	especially	as	 intratumoral	γδ	T	cells	 represents	the	most	 favorable	prognostic	 indicator	
across	diverse	cancers	(Gentles	et	al.,	2015).	γδ	T	cells	possess	unique	properties	that	make	them	
highly	amenable	for	immunotherapy.	They	are	relatively	abundant	in	human	blood	and	tissue	so	it	
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is	 possible	 to	 isolate	 them	 in	 relatively	 large	 numbers	 and	 most	 have	 a	 Th1-type	 cytokine	 bias	
(strong	 IFN-γ	 production)	 and	potent	 cytotoxicity	 potential,	 attributes	 that	 are	 closely	 correlated	
with	tumor	destruction.	They	readily	expand	following	TCR	stimulation	in	vitro,	thereby	increasing	
the	 feasibility	of	 their	usage	 in	adoptive	 transfer	models	of	 therapy	and	 furthermore,	many	γδ	T	
cells	have	unique	homing	properties	compared	to	αβ	T	cells,	typically	migrating	to	peripheral	sites,	
such	as	epithelial	tissues	and	solid	tumors.	Finally,	 like	other	unconventional	T	cells,	γδ	T	cells	are	
not	MHC	 restricted,	 so	 there	 are	 no	 genetic	 constraints	 to	 their	 antigen	 specific	 activation,	 and	
transferred	γδ	T	cells	 from	an	MHC	mismatched	background	do	not	cause	overt	graft-versus-host	
disease	(GVHD)	which	can	be	a	life-threatening	complication	with	adoptive	transfer	of	conventional	
αβ	T	cells	(Godder	et	al.,	2007;	Lamb	et	al.,	1996).		
	
Evidence	 for	 a	 role	 of	 γδ	 T	 cells	 in	 cancer	 surveillance	 first	 arose	 from	 studies	 using	 γδ	 T	 cell-
deficient	mice.	 These	 studies	 indicated	 a	 significantly	 elevated	 incidence	 of	 tumors	 in	models	 of	
chemically-induced	cutaneous	malignancies	(Gao	et	al.,	2003;	Girardi	et	al.,	2001)	and	spontaneous	
prostate	 adenocarcinoma	 (Liu	 et	 al.,	 2008),	 compared	 to	 control	 wild-type	 mice.	 Experimental	
transfer	 of	 established	 tumor	 cell	 lines	 derived	 from	 melanoma	 (Gao	 et	 al.,	 2003)	 and	 B	 cell	
lymphoma	 (Street	 et	 al.,	 2004)	 also	 confirmed	 a	 beneficial	 role	 of	 γδ	 T	 cells	 (reviewed	 in	 (Silva-
Santos	et	al.,	2015)).	Consistent	with	animal	 studies,	human	γδ	T	 cells	 can	also	elicit	 strong	anti-
tumor	 responses	 in	 vitro.	 Activated	 TRDV2+	 γδ	 T	 cells	 recognize	 and	 kill	 a	 broad	 range	 of	 tumor	
target	 cells	 in	 vitro	 (Bouet-Toussaint	 et	 al.,	 2008;	 Corvaisier	 et	 al.,	 2005;	 Kunzmann	 et	 al.,	 2000;	
Lanca	 et	 al.,	 2010;	 Liu	 et	 al.,	 2005;	 Viey	 et	 al.,	 2005).	 Likewise,	 activated	 TRDV1+	 cells	 can	 also	
recognize	 and	 kill	 diverse	 tumor	 lines	 representing	 many	 cancer	 types	 (Choudhary	 et	 al.,	 1995;	
Cordova	et	al.,	2012;	Correia	et	al.,	2011;	Groh	et	al.,	1999;	Lamb	et	al.,	2001;	Maeurer	et	al.,	1996).		
	
The	 association	 between	 γδ	 T	 cells	 and	 tumor	 progression	 and/or	 patient	 survival	 has	 been	
examined	in	a	range	of	different	human	tumor	settings,	with	contrasting	results.	Bialasiewicz	et	al.	
((Bialasiewicz	et	al.,	1999))	found	that	γδ	T	cells	amongst	tumor-infiltrating	lymphocytes	(TILs)	were	
positively	 associated	 with	 patient	 survival	 in	 choroidal	 melanoma.	 Another	 study	 of	 melanoma	
patients	found	that	TRDV2+	γδ	T	cells	were	positively	associated	with	survival	at	an	early	stage	of	
disease	(Cordova	et	al.,	2012),	and	a	follow	up	study	extended	this	correlation	with	overall	patient	
survival	 (Toia	 et	 al.,	 2016).	 Studies	 of	 patient	 cohorts	 that	 received	 allogeneic	 bone	 marrow	
transplantation	revealed	a	strong	correlation	between	γδ	T	cell	abundance	and	overall	survival	or	
disease-free	 survival	 in	 cohorts	 of	 ALL	 or	 acute	 myeloid	 leukemia	 (AML),	 or	 chronic	 myeloid	
leukemia	 (CML)	 patients	 (Godder	 et	 al.,	 2007;	 Lamb	 et	 al.,	 1996).	 Moreover,	 activated	 donor-
derived	γδ	T	cells,	which	were	predominantly	TRDV1+,	were	cytotoxic	against	recipient	ALL	tumors	
(Lamb	 et	 al.,	 2001)	 in	 vitro,	 suggesting	 a	 potentially	 important	 role	 for	 γδ	 T	 cells	 in	 immune	
surveillance	against	leukemia.	Despite	these	promising	findings,	in	some	settings	γδ	T	cells	do	not	
appear	 to	be	a	useful	prognostic	marker	 (Inman	et	al.,	 2008;	Kuriyama	et	al.,	 2000),	or	are	even	
associated	with	poor	outcome	or	tumor	burden,	indicative	of	a	pro-tumorigenic	role.	For	instance,	
in	 rectal	 cancer	 patients,	 while	 TRDV1+	 γδ	 T	 cells	 amongst	 TILs	 positively	 correlated	with	 tumor	
burden,	TRDV2+	cells	negatively	correlated,	 indicating	a	differential	role	of	these	subsets	(Rong	et	
al.,	 2016).	 Another	 study	 also	 found	 an	 association	 between	 IL17-producing	 γδ	 T	 cells	 and	 poor	
survival	in	gall	bladder	patients	(Patil	et	al.,	2016),	and	in	primary	breast	cancer	patients,	γδ	T	cells	
were	associated	with	more	severe	disease	and	reduced	overall	survival,	indicating	a	pro-tumor	role	
(Ma	 et	 al.,	 2012).	 In	 support	 of	 this	 notion,	 Peng	 et	 al.	 (Peng	 et	 al.,	 2007)	 isolated	 a	 regulatory	
population	of	TRDV1+	γδ	T	cells	from	breast	cancer	TILs	that	specifically	recognized	a	tumor	epitope	
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via	 the	γδTCR,	and	exhibited	 immune-suppressive	 functions	 that	 could	be	 reversed	 in	vitro	using	
TLR8	ligands.		
	
Further	 insight	 into	 the	 pro-	 versus	 anti-	 tumor	 role	 of	 γδ	 T	 cells	 can	 be	 gleaned	 from	 mouse	
studies.	 In	many	 cases,	 the	 protective	mechanisms	 appeared	 to	 involve	 interaction	with	 NK	 cell	
receptors	 such	 as	NKG2D,	which	 can	 recognize	 stress-associated	 receptors	 on	 transformed	 cells,	
along	with	IFNγ	production,	which	promotes	Th1	responses	that	are	generally	favorable	in	an	anti-
cancer	 immunotherapeutic	 setting.	 Another	 population	 of	 clonally	 expanded	 TRDV5+	 γδ	 T	 cells	
isolated	from	a	CMV-infected	patient	was	capable	of	killing	tumor	lines	through	recognition	of	the	
MHC-I	like	molecule	EPCR	(Willcox	et	al.,	2012),	suggesting	that	this	ligand	may	be	involved	in	γδ	T	
cell-mediated	 immunosurveillance,	 although	 further	 investigation	 is	 required.	 Whilst	 in	 some	
studies,	γδ	T	cell-derived	IL-17	exhibited	anti-tumor	effects	(Ma	et	al.,	2011;	Takeuchi	et	al.,	2011),	
it	 has	 also	 been	 associated	 with	 pro-tumor	 responses,	 along	 with	 regulatory	 cell-like	 functions,	
enhanced	angiogenesis,	and	neutrophil	or	MDSC	recruitment	(reviewed	 in	(Fleming	et	al.,	2017)).	
Collectively	 these	 studies	 highlight	 the	 importance	 of	 further	 research	 to	 understand	 the	 key	
factors	involved	in	driving	pro-	versus	anti-tumor	immunity	by	γδ	T	cells.		
	
There	have	now	been	~19	clinical	studies	examining	the	anti-cancer	potential	of	TRDV2+	γδ	T	cells	
in	a	range	of	cancer	settings	(Abe	et	al.,	2009;	Aoki	et	al.,	2017;	Bennouna	et	al.,	2008;	Bennouna	et	
al.,	2010;	Cui	et	al.,	2015a;	Dieli	et	al.,	2007;	Izumi	et	al.,	2013;	Kobayashi	et	al.,	2011;	Kobayashi	et	
al.,	2007;	Kunzmann	et	al.,	2012;	Lang	et	al.,	2011;	Meraviglia	et	al.,	2010;	Nakajima	et	al.,	2010;	
Nicol	et	al.,	2011b;	Pressey	et	al.,	2016;	Sakamoto	et	al.,	2011;	Wada	et	al.,	2014;	Wilhelm	et	al.,	
2003;	 Wilhelm	 et	 al.,	 2014)	 (Table	 2).	 These	 trials	 typically	 involved	 either	 in	 vitro	 or	 in	 vivo	
expansion	of	TRDV2+	γδ	T	cells	using	aminobisphosphonates,	such	as	zoledronate,	which	cause	an	
accumulation	 of	 the	 phosphoantigen	 isopentenyl	 pyrophosphate	 (IPP);	 or	 phosphoantigens	
directly.	Whilst	there	were	no	significant	adverse	effects	of	therapy	 in	these	studies,	complete	or	
even	partial	responses	were	relatively	infrequent,	although	of	note,	Wilhelm	et	al.	((Wilhelm	et	al.,	
2014))	 transferred	 HLA-half-matched,	 CD4	 and	 CD8-depleted	 cells	 into	 4	 patients	 with	
haematological	malignancies,	followed	by	in	vivo	γδ	T	cell	activation	using	zoledronate	and	IL-2,	of	
which	 3	 achieved	 a	 complete	 response.	 Kobayashi	 et	 al.	 also	 reported	 a	 patient	 that	 achieved	
complete	remission	from	renal	cell	carcinoma-derived	 lung	metastases	 following	zoledronate	and	
IL-2	therapy	(Kobayashi	et	al.,	2010).		
	
To	date	 there	have	been	no	clinical	 trials	performed	using	TRDV1+	γδ	T	cells,	although	they	were	
therapeutically	 beneficial	 in	 a	 xenogeneic	 model	 of	 human	 ovarian	 cancer,	 where	 adoptively	
transferred	 activated	 TRDV1	 cells	were	 largely	 protective	 (Deniger	 et	 al.,	 2014a),	 suggesting	 that	
clinical	studies	may	be	warranted.	Clearly	more	research	 is	required	to	understand	the	functional	
properties	 of	 γδ	 T	 cells,	 including	 their	 survival,	 homing,	 cytotoxic	 capacity	 and	 natural	 ligands	
(reviewed	in	(Deniger	et	al.,	2014b)),	prior	to	realizing	their	therapeutic	potential.	Future	therapies	
such	CAR	γδ	T	cell	therapy,	and	combination	therapies,	hold	much	promise	as	improved	treatment	
regimes.	
	
Concluding	remarks	
Unconventional	T	cells	and	immunotherapeutic	potential	in	humans:	future	prospects	
It	has	long	been	recognised	that	unconventional	T	cells	can	promote	tumor	rejection,	and	there	are	
many	reasons	why	 it	 is	of	value	to	translate	these	studies	to	clinical	trials.	Unconventional	T	cells	
offer	several	advantages	that	may	lead	to	improved	T	cell	immunotherapy	for	human	cancer.	These	
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include	the	ability	to	release	a	rapid	burst	of	cytokines	without	the	need	for	clonal	expansion	and	
differentiation,	in	part	due	to	the	presence	of	far	higher	numbers	of	Ag-specific	cells	that	exist	in	a	
poised,	memory-like	state	(Godfrey	et	al.,	2015).	For	example,	Ag-specific	NKT	cells,	MAIT	cells	and	
Vδ2+	 γδ	 T	 cells	 outnumber	 pMHC-specific	 CD8	 T	 cells	 by	 2-4	 orders	 of	 magnitude	 in	 humans	
(Godfrey	et	al.,	2015).	Furthermore,	the	adjuvant-like	effects	and	strong	cytokine	responses	upon	
activation	of	 some	of	 these	cells,	 such	as	 type	 I	NKT	cells,	engages	multiple	arms	of	 the	 immune	
system	 that	 should	 help	 to	 guard	 against	 the	 formation	 of	 tumor	 escape	 variants.	 The	 Ag-
presenting	 molecules	 for	 unconventional	 T	 cells	 are	 monomorphic	 and	 thus	 Ag-based	 vaccines	
targeting	these	cells	could	be	universally	effective	with	respect	to	human	cancer	patients.	This	also	
means	that	their	TCRs,	which	are	not	directed	toward	polymorphic	MHC	molecules,	will	be	unlikely	
to	mount	 alloreactive	 responses	 and	 cause	GVHD,	making	 these	 cells	more	 amenable	 to	 off	 the	
shelf	cellular	therapy	such	as	CAR-NKT	cell	therapy	(Heczey	et	al.,	2014;	Tian	et	al.,	2016).	Further,	
many	 of	 these	 unconventional	 T	 cells	 express	 TCRs	 with	 repeated	 patterns	 of	 TCR	 usage	 in	
unrelated	 individuals,	 which	 means	 that	 they	 could	 also	 potentially	 represent	 targets	 for	
immunotherapeutic	 intervention,	or	diagnostic	monitoring	 in	 tumor	 settings.	Moreover,	 the	non-
peptidic	nature	of	CD1	and	MR1	ligands	make	them	less	 likely	to	be	targets	of	mutational	escape	
within	the	tumor,	thereby	providing	more	stable	Ags	to	target	therapeutically.	Lastly,	in	contrast	to	
most	αβ	T	cells,	unconventional	T	cells	such	as	γδ	T	cells,	MAIT	cells	and	NKT	cells	naturally	home	to	
non-lymphoid	tissue	sites	which	is	an	important	characteristic	to	exploit	for	targeting	solid	tumors	
in	non-lymphoid	locations.	
	
While	 many	 clinical	 trials	 on	 unconventional	 T	 cells	 have	 focussed	 on	 the	 use	 of	 α-GalCer	 to	
stimulate	 type	 I	 NKT	 cells,	 future	 studies	 exploring	 the	 new	 lipid	 analogues	 (Figure	 2)	 should	
provide	 improved	 clinical	 outcomes.	Moreover,	 while	 targeting	 Ags	 recognised	 by	 group	 1	 CD1-
restricted	 T	 cells	 is	 in	 its	 infancy	 this	 also	warrants	 further	 investigation	 in	 the	 context	 of	 tumor	
immunotherapy.	Clinical	trials	targeting	TRDV1+	γδ	T	cells	may	offer	improved	outcomes	over	those	
targeting	TRDV2+	γδ	T	cells,	because	the	 former	tend	to	 localise	 to	non-lymphoid	tissue	 locations	
more	 so	 than	 the	 latter,	 suggesting	 they	 may	 be	 better	 at	 invading	 non-lymphoid	 tumors.	 The	
challenge	with	the	TRDV1+	cells	is	to	determine	which	Ags	they	respond	to	and	how	they	can	best	
be	harnessed	for	immunotherapy.	MAIT	cells	have	potential	as	targets	for	immunotherapy	due	to	
their	high	frequency	in	humans,	their	tissue	homing	characteristics,	and	the	existence	of	potent	Ags	
like	 5-OP-RU	 that	 can	 target	 these	 cells	 in	 all	 individuals.	 Studies	 using	 MR1	 restricted	 Ags	 in	
conjunction	with	tumor	vaccines	are	required	to	determine	if	MAIT	cells	have	similar	adjuvant-like	
activity	to	type	I	NKT	cells.	Based	on	the	promising	results	using	in	vitro	expanded	CAR-NKT	cells	in	
humanised	mouse	models,	 similar	 studies	using	CAR-MAIT	cells,	CAR-γδ	 T	and	CAR	MHC	class	 Ib-
restricted	T	cells	are	also	worthy	of	investigation.		
	
Checkpoint	 blockade	 therapy	 using	 anti-PD1	 and	 anti-CTLA-4	 based	 drugs	 to	 inhibit	 tumor-
mediated	immunosuppression	is	proving	to	be	a	very	powerful	approach	to	treating	some	types	of	
cancer	 (Melero	et	al.,	2015).	While	 this	 therapy	 is	usually	assumed	 to	act	primarily	via	enhanced	
CD8+	T	cell-mediated	tumor	destruction,	the	potential	role	that	unconventional	T	cells	play	should	
be	 considered,	 given	 that	 they	also	express	 the	 inhibitory	 receptors	 such	as	PD1	upon	activation	
and	 that	 blockade	 of	 these	 receptors	 can	 enhance	 their	 cytokine	 production	 and	 anti-tumor	
capacity	(Chang	et	al.,	2008b;	Durgan	et	al.,	2011;	Iwasaki	et	al.,	2011;	Jiang	et	al.,	2014).	Moreover,	
as	one	of	the	key	resistance	genes	associated	with	checkpoint	blockade	therapy	is	β2M	(Zaretsky	et	
al.,	 2016)	 which	 is	 associated	 with	 MHC	 class-Ia,	 MHC	 class-Ib,	 MR1	 and	 CD1	 family	 members,	
studies	into	the	role	that	each	of	these	T	cell	lineages	play	in	this	therapy	is	warranted.		
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These	are	exciting	times	in	the	field	of	T	cell	 immunotherapy	for	cancer,	and	the	incorporation	of	
unconventional	 T	 cells	 into	 these	 studies	 has	 the	 potential	 to	 provide	 novel	 approaches	 to	 this	
important	area	of	medicine.	
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Figure	legends	
Figure	1.	Unconventional	T	cell	types.	
Unconventional	 T	 cells,	 divided	 into	 groups	 based	 on	 their	 restriction	 elements.	 5-OP-RU,	 5-(2-
oxopropylideneamino)-6-D-ribitylaminouracil;	 6-FP,	 6-formylpterin;	 Ag,	 antigen;	 α-GalCer,	 α-
galactosylceramide;	GEM,	germline	encoded	mycolyl	lipid-reactive;	mLPA,	methyl	lysophosphatidic	
acid;	 MAIT,	 mucosal-associated	 invariant	 T;	 NKT,	 natural	 killer	 T;	 semi	 inv,	 semi-invariant;	 ?	 =	
insufficient	or	very	limited	data;	1	=	mostly	protective	but	suppressive	in	some	cases.	
	
Figure	2.	CD1-restricted	lipid-based	Ags	
Top	 left	 panel.	 A	 cartoon	 of	 a	 type	 I	 NKT	 cell	 recognising	 α-GalCer	 presented	 by	 a	 CD1d+	 Ag	
presenting	 cell.	 The	 ternary	 crystal	 structure	 of	 the	 TCR-CD1d-α-GalCer	 complex	 is	 shown	 in	 the	
inset.	 Top	 right	 panel.	 A	 sample	 of	 synthetic	 lipid	 analogues	 that	 have	 the	 ability	 to	 provide	
enhanced	and/or	Th1-biased	type	I	NKT	cell	responses.		Bottom	panel.	Examples	of	tumor-derived	
lipid	 Ags	 that	 are	 capable	 of	 being	 recognised	 by	 CD1d-restricted	 T	 cells,	 with	 the	 exception	 of	
mLPA	that	 is	recognised	by	CD1c-restricted	T	cells.	α-GalCer,	α-galactosylceramide;	mLPA,	methyl	
lysophosphatidic	acid;	NKT,	natural	killer	T	
	
Figure	3.	MR1-restricted	vitamin	B	metabolite	Ags	
Left	panel.	A	cartoon	of	a	MAIT	cell	recognising	a	vitamin	B	metabolite	presented	by	an	MR1+	Ag	
presenting	 cell.	 The	 ternary	 crystal	 structure	 of	 the	MAIT	 TCR-MR1-Ag	 complex	 is	 shown	 in	 the	
inset.	Right	panel.	Some	examples	of	vitamin-B	derivative	Ags	that	have	the	ability	to	bind	to	MR1	
and,	with	varying	degrees	of	potency,	to	stimulate	MAIT	cells	via	their	TCR.	The	exceptions	are	6-FP	
and	Acetyl-6-FP	(Ac-6-FP)	which	bind	MR1,	but	are	not	stimulatory	for	the	majority	of	MAIT	cells.	5-
OP-RU,	5-(2-oxopropylideneamino)-6-D-ribitylaminouracil;	6-FP,	6-formylpterin;	Ag,	antigen;	MAIT,	
mucosal-associated	invariant	T	
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Table	1.	NKT	cell	clinical	studies.	
	
Study	 Tumor	type	(N)	 Treatment	 Clinical	outcome	(N	=	%)	
(Giaccone	et	al.,	2002)	
Solid	tumors	(24)	
[not	defined]	
α-GalCer	(i.v.)	
Every	4	weeks	for	1-6	cycles	 OR	(0),	SD	(7	=29%	)	
(Nieda	et	al.,	2004)	
Solid	tumors	(12)	
[Breast	cancer	(1),	Colon	cancer	(1),	
Liver	cancer	(1),	Melanoma	(2),	
peritoneal/lung	AC	(4),	RCC	(3)]	
α-GalCer/immature	MoDC	(i.v.)	
Up	to	3	cyles	separated	by	several	months,	each	with	
2	infusions	
OR	(N.D.)	
Reduction	in	tumor	markers	or	
mass	(3	=	25%)	
(Nicol	et	al.,	2011a)	 As	above	
α-GalCer/immature	MoDC	(i.v.	and	intradermal)	
2	cycles	for	each	injection	route	over	2	months	
OR	[3	=	25%	(PR	3)],	SD	(3	=	
25%)	
(Chang	et	al.,	2005)	 MM	(3),	RCC	(1),	Anal	SCC	(1)	
α-GalCer/mature	MoDC	(i.v.)	
Every	month	for	2	cycles	
OR	(N.D.)	
Reduction	in	tumor	markers	or	
stable	metastatic	disease	(4	=	
80%)	
(Ishikawa	et	al.,	2005)	
NSCLC	(9)	
[lung	AC,	SCC,	LCC]	
α-GalCer/immature	DC-enriched	PBMC	
2	cycles	separated	by	6	weeks,	each	with	2	infusions	 OR	(0),	SD	(5	=	56%)	
(Motohashi	et	al.,	2006)	
NSCLC	(6)	
[AC	(4),	SCC	(2)]	
α-GalCer/IL-2-expanded	PBMC	(i.v.)	
Every	week	for	2	cycles	 OR	(0),	SD	(4	=	67%)	
(Uchida	et	al.,	2008)	 Head	and	neck	SCC	(9)	
α-GalCer/immature	DC-enriched	PBMC	(nasal	
submucosa)	
Every	week	for	2	cycles	
OR	[(1	=	11%	(PR	1)],	SD	(5	=	
56%)	
(Motohashi	et	al.,	2009)	
NSCLC	(17)	
[AC	(14),	SCC	(3)]	
α-GalCer/immature	DC-enriched	PBMC	(i.v.)	
2	cycles	separated	by	6	weeks,	each	with	2	infusions	 SD	(5	=	29%)	
(Kunii	et	al.,	2009)	 Head	and	neck	SCC	(8)	
α-GalCer/immature	DC-enriched	PBMC	(nasal	
submucosa)	+		
α-GalCer/IL-2-expanded	PBMC	(arterial	infusion)	
Every	week	for	2	cycles	
OR	[3	=	38%	(PR	3)],	SD	(4	=	
50%)	
(Yamasaki	et	al.,	2011)	 Head	and	neck	SCC	(10)	
α-GalCer/immature	DC-enriched	PBMC	(nasal	
submucosa)	+		
α-GalCer/IL-2-expanded	PBMC	(arterial	infusion)	+	
surgery	
Enriched	NKT	injected	1	week	after	APCs,	followed	
by	surgery	
OR	[5	=	50%	(PR	5)],	SD	(5	=	
50%)	
(Kurosaki	et	al.,	2011)	 Head	and	neck	SCC	(17)	
α-GalCer/immature	DC-enriched	PBMC	(nasal	or	oral	
submucosa)	
Undefined	number	of	injections	
OR	(N.D.)	
Increased	NKT	number	in	PBMC	
(Nagato	et	al.,	2012)	
NSCLC	(4)	
[AC	1,	SCC	3]	
α-GalCer/immature	DC-enriched	PBMC	(i.v.)	
Single	injection	2	weeks	prior	to	surgery	
OR	(N.D.)	
Increased	NKT	infiltration	of	
TILs	
(Richter	et	al.,	2012)	 Asymptomatic	MM	(6)	
α-GalCer/mature	MoDC	(i.v.)	+	lenalidomide	(i.v.)	
Every	4	weeks	for	3	cycles	
OR	(N.D.)	
Reduction	in	tumor	markers	(3	
=	50%)	
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Table	2.	γδ	T	cell	clinical	studies.	
Study	 Tumor	type	(N)	 Treatment	 Clinical	outcome	(N	=	%)	
(Wilhelm	et	al.,	2003)	
cohort	A	
MM	(3),	FCL	(0),	CLL	(4),	MZL	(1),	IC	
(1)	
Pamidronate	(i.v.	day	0)	+		IL-2	(24h	infusion	i.v.		
day	3-8)	
1-6	cycles	 OR	(0),	SD	(1	=	13%)	
(Wilhelm	et	al.,	2003)	
cohort	B	
MM	(4),	FCL	(4),	CLL	(0),	MZL	(1),	IC	
(0)	
Pamidronate	(i.v.	day	0)	+	IL-2	(6h	infusion	i.v.		
days	1-6)	
1-9	cycles	
OR	[3	=	33%	(PR	3)],	SD	(2	=	
22%)	
(Dieli	et	al.,	2007)	
cohort	A	 HRPC	(9)	
Zol	(i.v.)	
Every	3	weeks	for	up	to	1	year.	
OR	[1	=	11%	(PR	1)],	SD	(1	=	
11%)	
(Dieli	et	al.,	2007)	
cohort	B	 HRPC	(9)	
Zol	(i.v.)	+	IL-2	(s.c.)	
Every	3	weeks	for	up	to	1	year.	
OR	[2	=	22%	(PR	2)],	SD	(4	=	
44%)	
(Kobayashi	et	al.,	2007)	 RCC	(7)	
pAg/IL-2-expanded	PBMC	(i.v.)	+	IL-2	(i.v.)	
	Every	1-2	weeks	for	6-12	cycles.	
OR	(N.D.)	
Tumor	doubling	time	prolonged	
in	3	patients.	
(Bennouna	et	al.,	2008).	 RCC	(10)	
pAg/IL-2-expanded	PBMC	(i.v.)	+	IL-2	(s.c.)	
Every	3	weeks	for	3	cycles.	 OR	(0),	SD	(6	=	60%)	
(Abe	et	al.,	2009)	 MM	(6)	
Zol/IL-2-expanded	PBMC	(i.v.)	
Every	2	weeks	for	4-8	cycles	 OR	(0),	SD	(4	=	67%)	
(Bennouna	et	al.,	2010)	
RCC	(18),	Colon	cancer	(3),	
Esophagus	carcinoma	(3),	Breast	
cancer	(2),	Ovarian	cancer	(1),	
Gastric	cancer	(1)	
pAg	(i.v.)	+	IL-2	(s.c.)	
Every	3	weeks	for	up	to	5	cycles	 OR	(0),	SD	(12	=	43%)	
(Meraviglia	et	al.,	2010)	 Breast	cancer	(10)	
Zol	(i.v.)	+	IL-2	(s.c.)	
3	week	cycles	for	up	to	1	year	
OR	[1	=	10%	(PR	1)],	SD	(2	=	
20%)	
(Nakajima	et	al.,	2010)	
NSCLC	(10)	
[AC	(8),	SCC	(1),	LCC	(1)]	
Zol/IL-2-expanded	PBMC	(i.v.)	
Every	2	weeks	for	3-12	cycles	 OR	(0),	SD	(3	=	30%)	
(Kobayashi	et	al.,	2011)	 RCC	(11)	
pAg-expanded	PBMC	(i.v.)	+	Zol	(i.v.)	+	IL-2	
Every	4	weeks	for	1-6	cycles	
OR	[(1	=	9%	(CR	1)],	SD	(5	=	
45%)	
(Lang	et	al.,	2011)	 RCC	(11)	
Zol	(i.v.)	+	IL-2	(s.c.)	
Every	4	weeks	for	1-10	cycles	 OR	(0),	SD	(2	=	22%)	
(Nicol	et	al.,	2011b)	
cohort	A/B	
Melanoma	(7),	Ovarian	cancer	(2),	
Colon/duodenal-cancer	(4),	Bone	AC	
(1),	Cholangiocarcinoma	(1)	
Zol/IL-2-expanded	PBMC	(i.v.)	+	Zol	(i.v.)	
6-8	cycles	 OR	(0),	SD	(3	=	20%)	
(Nicol	et	al.,	2011b)	
cohort	C	 Breast	cancer	(2),	Cervical	cancer	(1)	
Zol/IL-2-expanded	PBMC	(i.v.)	+	Zol	(i.v.)	+	
conventional	therapy	
7-8	cycles	 OR	[3	=	100%	(CR	1,	PR	2)]	
(Sakamoto	et	al.,	2011)	
NSCLC	(15)	
[AC	(11),	SCC	(2),	LCNEC	(1),	,	LCC	
(1)]	
Zol/IL-2-expanded	PBMC	(i.v.)	
6	cycles	 OR	(0),	SD	(6	=	40%)	
(Kunzmann	et	al.,	2012)	
RCC	(7)	
Melanoma	(6)	
AML	(8)	
Zol	(i.v.)	+	IL-2	(s.c.)	
Every	4	weeks	for	1-6	cycles	
OR	[(2	=	10%	(PR	2)],	SD	(6	=	
29%)	
(Izumi	et	al.,	2013)	 CRC	(6)	
Zol/IL-2-expanded	PBMC	(i.v.)	
Every	week	for	8	cycles	 OR	(N.D.)	
(Wilhelm	et	al.,	2014)	 T-NHL	(1),	AML	(1),	SPL	(1),	MM	(1)	
Conditioning	chemotherapy	+	CD4/CD8-depleted	
half-matched		
PBMC	(i.v.)	+	Zol	(i.v.)	+	IL-2	(s.c.)	 OR	[3	=	75%	(CR	3)]	
(Wada	et	al.,	2014)	 Gastric	cancer	(7)	
Zol/IL-2-expanded	PBMC	(i.p.)	+	Zol	(i.v.	and	i.p.)	
Every	week	for	4	cycles	
OR	(N.D.)	
Reduction	in	tumor	ascites	
(Cui	et	al.,	2015a)	 Gastric	cancer	(30)	
Chemotherapy	+	γδ	T/NK/cytokine-induced	killer	
therapy	
Up	to	6	infusions	every	3	weeks	
Significant	improvement	in	
progression-free	
survival	over	chemotherapy	
alone	
(Pressey	et	al.,	2016)	 Neuroblastoma	(4)	
Zol	i.v.	+	IL-2	s.c.	
Every	4	weeks	for	1-3	cycles	 OR	(0),	SD	(1	=	25%)	
(Aoki	et	al.,	2017)	 Pancreatic	adenocarcinoma	(28)	
Chemotherapy	+	Zol/IL-2-expanded	PBMC	
Every	4	weeks	for	6	cycles	
No	improvement	over	
chemotherapy	alone	
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Abbreviations:	Objective	response	(OR),	partial	remission	(PR)	and	stable	disease	(SD)	defined	by	
criteria	in	each	study.	Acute	myeloid	leukemia	(AML),	adenocarcinoma	(AC),	Chronic	lymphocytic	
leukemia	(CLL),	Follicle	center	lymphoma	(FCL),	hormone-refractory	prostate	cancer	(HRPC),	
immunocytoma	(IC),	large-cell	carcinoma	(LCC),	large	cell	neuroendcrine	carcinoma	(LCNEC),	
mantle	zone	lymphoma	(MZL),	multiple	myeloma	(MM),	non-small-cell	lung	cancer	(NSCLC),	renal	
cell	carcinoma	(RCC),	squamous	cell	carcinoma	(SCC),	Secondary	Plasma	Cell	Leukaemia	(SPL),	T-cell	
Non-Hodgkin	lymphoma	(T-NHL),	zoledronate	(Zol).	ND,	not	determined;	pAg,	phosphoantigen;	ip,	
intra-peritoneal;	iv,	intra-venous;	sc,	sub-cutaneous;	TILs,	tumor-infiltrating	lymphocytes.	
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